



Decision Diagnostics Corp.

**QUARTERLY REPORT FOR
OTC MARKETS**

Supplemental Disclosures

**Quarterly Report for the
Three Months Ended
June 30, 2021**

Trading Symbol: DECN
CUSIP Number: 243443 108

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Decision Diagnostics Corp.

A Nevada Corporation

2660 Townsgate Road Suite 300

Westlake Village, CA 92361

(805) 446-1973

www.decisiondiagnostics.com

info@desisiocdiagnostics.com

5122, 7371

Quarterly Report

For the Period Ending: March 31, 2021
(the "Reporting Period")

As of June 30, 2021, the number of shares outstanding of our Common Stock was:

357,060,583

As of December 31, 2020, the number of shares outstanding of our Common Stock was:

354,495,583

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐

No: ☒ (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐

No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: ☐

No: ☒

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

11/25/2011 Company named changed from Instacare Corp. to Decision Diagnostics Corp.

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable) Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada, active

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

2) Security Information

Trading symbol:	<u>DECN</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>243443 108</u>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>495,000,000</u>	as of (since) date: <u>November 25, 2011</u>
Total shares outstanding:	<u>357,060,583</u>	as of date: <u>June 30, 2021</u>
Number of shares in the Public Float ² :	<u>354,495,583</u>	as of (since) date: <u>December 31, 2020</u>
Total number of shareholders of record:	<u>483</u>	as of date: <u>June 30, 2021</u>

Additional class of securities (if any): N/A

Trading symbol:	_____	
Exact title and class of securities outstanding:	_____	
CUSIP:	_____	
Par or stated value:	_____	
Total shares authorized:	_____	as of date: _____
Total shares outstanding:	_____	as of date: _____

Transfer Agent

Name: Action Stock Transfer
Phone: (801) 274-1088
Email: jb@actionstocktransfer.com

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

On April 23, 2020 the United States Securities and Exchange Commission suspended trading in the company's stock for a period of 10 days. The company appealed this suspension. Fifteen months have passed since the last pleadings were filed in this matter and the SEC has not responded, pleaded or held a hearing. The company thus believes its appeal of the suspension was successful. In December, 2020 the company and its CEO Keith Berman were sued in Federal District Court in New York by the U.S. Securities and Exchange Commission (SEC). The SEC action sought injunctive and other relief based on allegedly false and misleading information

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

contained in a series of press releases issued by the company concerning the development and potential sales of the company's GenViroCovid test kits. This lawsuit was almost immediately stayed by the Federal court and no subsequent activity has taken place.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period. See Table below.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
1/8/18	New Issuance	1,504,281	Common		No		Debt conversion	Restricted	Section 144
1/18/18	New Issuance	100,000	Preferred "E"		No		Financing cost	Restricted	Section 144
2/9/18	New Issuance	1,496,661	Common		No		Debt conversion	Restricted	Section 144
2/23/18	Conversion	(100,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
2/23/18	Conversion	1,400,000	Common		No		Share exchange	Restricted	Section 144
2/23/18	Conversion	(70,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
2/23/18	Conversion	980,000	Common		No		Share exchange	Restricted	Section 144
3/5/18	New Issuance	1,510,797	Common		No		Debt conversion	Restricted	Section 144
3/31/18	New Issuance	1,521,904	Common		No		Debt conversion	Restricted	Section 144
4/3/18	New Issuance	849,123	Common		No		Financing cost	Restricted	Section 144
4/16/18	New Issuance	1,513,789	Common		No		Share exchange	Restricted	Section 144
4/16/18	New Issuance	100,000	Preferred "E"		No		Financing cost	Restricted	Section 144
4/23/18	New Issuance	1,039,571	Common		No		Share exchange	Restricted	Section 144
5/11/18	New Issuance	420	Preferred "C"		No		Financing cost	Restricted	Section 144
5/11/18	New Issuance	100,000	Preferred "E"		No		Financing cost	Restricted	Section 144
5/29/18	New Issuance	1,985,374	Common		No		Debt conversion	Restricted	Section 144
5/29/18	New Issuance	1,550,000	Common		No		Debt conversion	Restricted	Section 144
6/11/18	Conversion	(75,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
6/11/18	Conversion	1,050,000	Common		No		Share exchange	Restricted	Section 144
6/30/18	New Issuance	14,300	Preferred "E"		No		N/A	Restricted	Section 144

6/30/18	New Issuance	10,000	Common		No		N/A	Restricted	Section 144
7/3/18	New Issuance	1,520,646	Common		No		Debt conversion	Restricted	Section 144
7/30/18	Conversion	(125)	Preferred "C"		No		Share exchange	Restricted	Section 144
7/30/18	Conversion	625,000	Common		No		Share exchange	Restricted	Section 144
7/30/18	Conversion	(125)	Preferred "C"		No		Share exchange	Restricted	Section 144
7/30/18	Conversion	625,000	Common		No		Share exchange	Restricted	Section 144
7/31/18	New Issuance	710	Preferred "C"		No		Financing cost	Restricted	Section 144
7/31/18	New Issuance	105	Preferred "C"		No		Financing cost	Restricted	Section 144
7/31/18	New Issuance	50	Preferred "D"		No		Financing cost	Restricted	Section 144
7/31/18	New Issuance	10	Preferred "D"		No		Financing cost	Restricted	Section 144
7/31/18	New Issuance	200,000	Preferred "E"		No		Financing cost	Restricted	Section 144
8/23/18	Conversion	(35,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
8/23/18	Conversion	490,000	Common		No		Share exchange	Restricted	Section 144
8/23/18	Conversion	(50,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
8/23/18	Conversion	700,000	Common		No		Share exchange	Restricted	Section 144
8/27/18	New Issuance	816,326	Common		No		Financing cost	Restricted	Section 144
10/9/18	New Issuance	1,031,758	Common		No		Debt conversion	Restricted	Section 144
11/26/18	Conversion	(50,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
11/26/18	Conversion	700,000	Common		No		Share exchange	Restricted	Section 144
11/26/18	Conversion	(100,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
11/26/18	Conversion	1,400,000	Common		No		Share exchange	Restricted	Section 144
1/2/19	New Issuance	420	Preferred "C"		No		Financing cost	Restricted	Section 144
1/2/19	New Issuance	140	Preferred "C"		No		Financing cost	Restricted	Section 144
1/2/19	New Issuance	10	Preferred "D"		No		Financing cost	Restricted	Section 144
2/5/19	New Issuance	5,004,552	Common		No		Debt conversion	Restricted	Section 144
2/13/19	New Issuance	600,000	Common		No		Consulting services	Restricted	Section 144
3/12/19	Conversion	(100,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
3/12/19	Conversion	1,400,000	Common		No		Share exchange	Restricted	Section 144
4/1/19	New Issuance	4,139,272	Common		No		Debt conversion	Restricted	Section 144
4/5/19	New Issuance	600,000	Common		No		Financing cost	Restricted	Section 144
5/1/19	New Issuance	413,218	Common		No		Financing cost	Restricted	Section 144
5/1/19	New Issuance	1,091,718	Common		No		Financing cost	Restricted	Section 144
5/1/19	New Issuance	1,395,555	Common		No		Financing cost	Restricted	Section 144
5/8/19	New Issuance	420	Preferred "C"		No		Financing cost	Restricted	Section 144
5/8/19	New Issuance	140	Preferred "C"		No		Financing cost	Restricted	Section 144
5/8/19	New Issuance	10	Preferred "D"		No		Financing cost	Restricted	Section 144
5/8/19	New Issuance	30	Preferred "D"		No		Financing cost	Restricted	Section 144
5/8/19	New Issuance	15	Preferred "D"		No		Financing cost	Restricted	Section 144
5/8/19	New Issuance	15	Preferred "D"		No		Financing cost	Restricted	Section 144
5/8/19	New Issuance	175,000	Preferred "E"		No		Consulting services	Restricted	Section 144
5/8/19	New Issuance	150,000	Preferred "E"		No		Consulting services	Restricted	Section 144
6/11/19	New Issuance	600,000	Common		No		Financing cost	Restricted	Section 144
6/19/19	New Issuance	4,083,006	Common		No		Debt conversion	Restricted	Section 144
7/11/19	New Issuance		Common		No		Financing cost	Restricted	Section 144

		2,800,000							
7/16/19	New Issuance	400	Preferred "B"		No		Financing cost	Restricted	Section 144
7/16/19	New Issuance	210	Preferred "B"		No		Financing cost	Restricted	Section 144
7/16/19	New Issuance	130	Preferred "B"		No		Financing cost	Restricted	Section 144
7/16/19	New Issuance	260	Preferred "B"		No		Financing cost	Restricted	Section 144
7/16/19	New Issuance	210	Preferred "C"		No		Financing cost	Restricted	Section 144
7/16/19	New Issuance	70	Preferred "C"		No		Financing cost	Restricted	Section 144
7/16/19	New Issuance	10	Preferred "D"		No		Financing cost	Restricted	Section 144
10/9/19	New Issuance	300,000	Preferred "E"		No		Share exchange	Restricted	Section 144
10/11/19	New Issuance	210	Preferred "C"		No		Financing cost	Restricted	Section 144
10/11/19	New Issuance	105	Preferred "C"		No		Financing cost	Restricted	Section 144
10/11/19	New Issuance	10	Preferred "D"		No		Financing cost	Restricted	Section 144
10/29/19	New Issuance	1,400,000	Common		No		Share exchange	Restricted	Section 144
10/29/19	New Issuance	(100,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
11/15/19	New Issuance	600,000	Common		No		Financing cost	Restricted	Section 144
12/31/19	New Issuance	720,000	Common		No		Financing cost	Restricted	Section 144
12/31/19	New Issuance	210	Preferred "C"		No		Financing cost	Restricted	Section 144
12/31/19	New Issuance	70	Preferred "C"		No		Financing cost	Restricted	Section 144
12/31/19	New Issuance	10	Preferred "D"		No		Financing cost	Restricted	Section 144
1/22/20	New Issuance	600,000	Common		No		Financing cost	Restricted	Section 144
3/10/20	New Issuance	120,000	Preferred "E"		No		Financing cost	Restricted	Section 144
3/10/20	New Issuance	30,000	Preferred "E"		No		Financing cost	Restricted	Section 144
3/11/20	New Issuance	5,167,593	Common		No		Debt conversion	Restricted	Section 144
3/12/20	New Issuance	3,504,205	Common		No		Debt conversion	Restricted	Section 144
3/13/20	New Issuance	3,903,387	Common		No		Debt conversion	Restricted	Section 144
3/13/20	New Issuance	1,680,000	Common		No		Share exchange	Restricted	Section 144
3/13/20	New Issuance	(120,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
3/16/20	New Issuance	3,852,572	Common		No		Debt conversion	Restricted	Section 144
3/16/20	New Issuance	420,000	Common		No		Share exchange	Restricted	Section 144
3/16/20	New Issuance	(30,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
3/18/20	New Issuance	4,074,376	Common		No		Debt conversion	Restricted	Section 144
3/19/20	New Issuance	2,450,000	Common		No		Share exchange	Restricted	Section 144
3/19/20	New Issuance	(175,000)	Preferred "E"		No		Share exchange	Restricted	Section 144
3/19/20	New Issuance	600,000	Common		No		Financing cost	Restricted	Section 144
3/20/20	New Issuance	5,060,718	Common		No		Debt conversion	Restricted	Section 144
3/24/20	New Issuance	5,066,462	Common		No		Debt conversion	Restricted	Section 144
3/31/20	New Issuance	4,014,359	Common		No		Debt conversion	Restricted	Section 144
4/1/20	New Issuance	5,250,000	Common		No		Share exchange	Restricted	Section 144
4/2/20	New Issuance	4,231,624	Common		No		Debt conversion	Restricted	Section 144
4/3/20	New Issuance	631,178	Common		No		Financing cost	Restricted	Section 144
4/3/20	New Issuance	1,767,298	Common		No		Financing cost	Restricted	Section 144
4/3/20	New Issuance	879,477	Common		No		Financing cost	Restricted	Section 144
4/7/20	New Issuance	1,875,000	Common		No		Share exchange	Restricted	Section 144
4/7/20	New Issuance	2,480,103	Common		No		Debt conversion	Restricted	Section 144

4/7/20	New Issuance	1,835,259	Common		No		Debt conversion	Restricted	Section 144
4/7/20	New Issuance	1,500,000	Common		No		Financing cost	Restricted	Section 144
4/8/20	New Issuance	4,550,803	Common		No		Debt conversion	Restricted	Section 144
4/8/20	New Issuance	4,828,006	Common		No		Debt conversion	Restricted	Section 144
4/13/20	New Issuance	4,553,436	Common		No		Debt conversion	Restricted	Section 144
4/17/20	New Issuance	5,500,000	Common		No		Share exchange	Restricted	Section 144
4/17/20	New Issuance	1,318,340	Common		No		Financing cost	Restricted	Section 144
4/17/20	New Issuance	4,830,548	Common		No		Financing cost	Restricted	Section 144
4/20/20	New Issuance	4,841,966	Common		No		Debt conversion	Restricted	Section 144
4/22/20	New Issuance	3,756,851	Common		No		Debt conversion	Restricted	Section 144
4/22/20	New Issuance	1,009,757	Common		No		Debt conversion	Restricted	Section 144
4/22/20	New Issuance	210	Preferred "C"		No		Share exchange	Restricted	Section 144
4/22/20	New Issuance	240,000	Common		No		Share exchange	Restricted	Section 144
4/22/20	New Issuance	10	Preferred "D"		No		Share exchange	Restricted	Section 144
4/22/20	New Issuance	70	Preferred "C"		No		Share exchange	Restricted	Section 144
4/23/20	New Issuance	4,873,000	Common		No		Debt conversion	Restricted	Section 144
5/8/20	New Issuance	4,567,644	Common		No		Debt conversion	Restricted	Section 144
5/8/20	New Issuance	2,100,000	Common		No		Share exchange	Restricted	Section 144
5/13/20	New Issuance	4,523,162	Common		No		Debt conversion	Restricted	Section 144
5/18/20	New Issuance	2,837,500	Common		No		Financing cost	Restricted	Section 144
5/18/20	New Issuance	3,750,561	Common		No		Financing cost	Restricted	Section 144
5/18/20	New Issuance	1,225,000	Common		No		Share exchange	Restricted	Section 144
5/18/20	New Issuance	4,800,000	Common		No		Share exchange	Restricted	Section 144
5/19/20	New Issuance	600,000	Common		No		Financing cost	Restricted	Section 144
5/21/20	New Issuance	4,532,376	Common		No		Debt conversion	Restricted	Section 144
5/22/20	New Issuance	2,040,000	Common		No		Share exchange	Restricted	Section 144
5/28/20	New Issuance	4,818,234	Common		No		Debt conversion	Restricted	Section 144
6/10/20	New Issuance	4,283,652	Common		No		Debt conversion	Restricted	Section 144
7/7/20	New Issuance	(136)	Preferred "B"		No		Share exchange	Restricted	Section 144
7/7/20	New Issuance	2,040,000	Common		No		Share exchange	Restricted	Section 144
7/21/20	New Issuance	210	Preferred "C"		No		Financing cost	Restricted	Section 144
7/21/20	New Issuance	70	Preferred "C"		No		Financing cost	Restricted	Section 144
7/21/20	New Issuance	10	Preferred "D"		No		Financing cost	Restricted	Section 144
7/21/20	New Issuance	2,400,000	Common		No		Financing cost	Restricted	Section 144
8/17/20	New Issuance	5,026,179	Common		No		Debt conversion	Restricted	Section 144
8/19/20	New Issuance	(63)	Preferred "B"		No		Share exchange	Restricted	Section 144
8/19/20	New Issuance	945,000	Common		No		Share exchange	Restricted	Section 144
8/24/20	New Issuance	(20)	Preferred "D"		No		Share exchange	Restricted	Section 144
8/24/20	New Issuance	2,400,000	Common		No		Share exchange	Restricted	Section 144
9/18/20	New Issuance	5,070,154	Common		No		Debt conversion	Restricted	Section 144
6/10/20	New Issuance	4,283,652	Common		No		Debt conversion	Restricted	Section 144
7/7/20	New Issuance	(136)	Preferred "B"		No		Share exchange	Restricted	Section 144
7/7/20	New Issuance	2,040,000	Common		No		Share exchange	Restricted	Section 144
7/21/20	New Issuance		Preferred "C"		No		Financing cost	Restricted	Section 144

		210							
7/21/20	New Issuance	70	Preferred "C"		No		Financing cost	Restricted	Section 144
7/21/20	New Issuance	10	Preferred "D"		No		Financing cost	Restricted	Section 144
7/21/20	New Issuance	2,400,000	Common		No		Financing cost	Restricted	Section 144
8/17/20	New Issuance	5,026,179	Common		No		Debt conversion	Restricted	Section 144
8/19/20	New Issuance	(63)	Preferred "B"		No		Share exchange	Restricted	Section 144
8/19/20	New Issuance	945,000	Common		No		Share exchange	Restricted	Section 144
8/24/20	New Issuance	(20)	Preferred "D"		No		Share exchange	Restricted	Section 144
8/24/20	New Issuance	2,400,000	Common		No		Share exchange	Restricted	Section 144
9/18/20	New Issuance	5,070,154	Common		No		Debt conversion	Restricted	Section 144

10/05/2020	New Issuance	5,087,744	Common		No		Financing cost	Restricted	Section 144
10/05/2020	New Issuance	360,000	Common		No		Financing cost	Restricted	Section 144
10/05/2020	New Issuance	180,000	Common		No		Financing cost	Restricted	Section 144
10/05/2020	New Issuance	180,000	Common		No		Financing cost	Restricted	Section 144
10/05/2020	New Issuance	720,000	Common		No		Financing cost	Restricted	Section 144
10/05/2020	New Issuance	360,000	Common		No		Financing cost	Restricted	Section 144
10/05/2020	New Issuance	360,000	Common		No		Financing cost	Restricted	Section 144
10/14/2020	New Issuance	600,000	Common		No		Debt Conversion	Restricted	Section 144
10/19/2020	New Issuance	5,672,593	Common		No		Debt conversion	Restricted	Section 144

11/10/20	New Issuance	600,000	Common		No		Debt Conversion	Restricted	Section 144
11/13/20	New Issuance	3,522,546	Common		No		Financing cost	Restricted	Section 144
11/16/2020	New Issuance	6,935,613	Common		No		Financing cost	Restricted	Section 144
12/03/2020	New Issuance	1,765,000	Common		No		Share Exchange	Restricted	Section 144
12/03/2020	New Issuance	6,658,356	Common		No		Financing cost	Restricted	Section 144
12/15/2020	New Issuance	4,753,790	Common		No		Financing cost	Restricted	Section 144

01/12/2021	New Issuance	360,000	Common		No		Financing Cost	Restricted	Section 144
01/12/2021	New Issuance	180,000	Common		No		Financing cost	Restricted	Section 144
01/12/2021	New Issuance	180,000	Common		No		Financing cost	Restricted	Section 144
01/21/2021	New Issuance	1,125,000	Common		No		Share Exchange	Restricted	Section 144

04/13/2021	New Issuance	360,000	Common		No		Financing Cost	Restricted	Section 144
04/13/2021	New Issuance	180,000	Common		No		Financing cost	Restricted	Section 144
04/13/2021	New Issuance	180,000	Common		No		Financing cost	Restricted	Section 144

- (1) Alpha Capital Anstalt is an entity controlled by its Board of Directors. The managing directors are Konrad Ackerman and Nicole Feuerstein.
- (2) Chase Financing Inc. and Chase Financing Inc. Profit Sharing and 401K Plan are entities controlled by Robert Herskowitz and Mark Herskowitz.
- (3) Paradigm Capital Partners LLC, Navasink Device Initiatives LLC, Sovereign Partners LLC and LICGO Partners LLC, and their agent Edward Feighan are entities controlled, in equal parts by Alan Goddard and Michael Lichtenstein.
- (4) Cadence Holdings LLC and TPC Holdings Group LLC are entities controlled in equal parts by Steven Pollan and Daniel Meyers.
- (5) Mayer and Associates LLC is an entity controlled by Benjamin Mayer.
- (6) OmniVance Advisors has ceased operations to the best of our knowledge.
- (7) Keith Berman, current CEO through March 31, 2021 accepted stock options in lieu of salary. Commencing in April 2021 Mr. Berman began receiving a salary not to exceed \$8,000.00 monthly. In 2018, 2019, 2020 and 2021 Mr. Berman did not purchase or accept any shares of stock
- (8) Thomas Nelson and the KEN and JAN Stock Trusts are all partnerships and/or Trusts controlled by Thomas Nelson and his agents inclusive of Ken Schaefer

Use the space below to provide any additional details, including footnotes to the table above:

COMMON STOCK

Date		Description	Change in Shares	Running Total
1/8/2018	New Issuance-Alpha Capital Anstalt	1,504,281	111,745,891	
2/9/2018	New Issuance-Alpha Capital Anstalt	1,496,661	113,242,552	
2/23/2018	New Issuance-Robert Herskowitz	1,400,000	114,642,552	
2/23/2018	New Issuance-Chase Financing Inc Profit Sh.	980,000	115,622,552	
3/5/2018	New Issuance-Alpha Capital Anstalt	1,510,797	117,133,349	
4/2/2018	New Issuance-Alpha Capital Anstalt	1,521,904	118,655,253	
4/3/2018	New Issuance-Mark Herskowitz	849,123	119,504,376	
4/16/2018	New Issuance-Alpha Capital Anstalt	1,513,789	121,018,165	
4/23/2018	New Issuance-Alpha Capital Anstalt	1,039,571	122,057,736	
5/29/2018	New Issuance-Alpha Capital Anstalt	1,985,374	124,043,110	
5/29/2018	New Issuance-Robert Herskowitz	1,550,000	125,593,110	
6/11/2018	New Issuance-Chase Financing Inc Profit Sh.	1,050,000	126,643,110	
7/3/2018	New Issuance-Alpha Capital Anstalt	1,520,646	128,163,756	
7/30/2018	New Issuance-WilCo	625,000	128,788,756	
7/30/2018	New Issuance-WilCo	625,000	129,413,756	
8/23/2018	New Issuance-Chase Financing Inc Profit Sh.	490,000	129,903,756	
8/23/2018	New Issuance-Chase Financing	700,000	130,603,756	
8/27/2018	New Issuance-Mark Herskowitz	816,326	131,420,082	
10/9/2018	New Issuance-Alpha Capital Anstalt	1,031,758	132,451,840	
11/26/2018	New Issuance-Chase Financing Inc Profit Sh.	700,000	133,151,840	
11/26/2018	New Issuance-Chase Financing Inc Profit Sh.	1,400,000	134,551,840	
2/5/2019	New Issuance-Alpha Capital Anstalt	5,004,552	139,556,392	
2/13/2019	New Issuance-Mark Herskowitz	600,000	140,156,392	
3/12/2019	New Issuance-Chase Financing Inc Profit Sh.	1,400,000	141,556,392	
4/1/19	New Issuance-Alpha Capital Anstalt	4,139,272	145,695,664	
4/5/19	New Issuance-Mark Herskowitz	600,000	146,295,664	
5/1/19	New Issuance-Chase Financing Inc	413,218	146,708,882	
5/1/19	New Issuance-Robert Herskowitz	1,091,718	147,800,600	
5/1/19	New Issuance-Chase Financing Inc Profit Sh.	1,395,555	149,196,155	
6/11/19	New Issuance-Mark Herskowitz	600,000	149,796,155	
6/19/19	New Issuance-Alpha Capital Anstalt	4,083,006	153,879,161	
7/11/19	New Issuance-Chase Financing Inc Profit Sh.	2,800,000	156,679,161	
10/29/19	New Issuance-Chase Financing Inc Profit Sh.	1,400,000	158,079,161	
11/15/19	New Issuance-Mark Herskowitz	600,000	158,679,161	
12/31/19	New Issuance- Chase Financing	720,000	159,399,161	
1/22/20	New Issuance-Mark Herskowitz	600,000	159,999,161	

3/11/20	New Issuance-Alpha Capital Anstalt	5,167,593	165,166,754
3/12/20	New Issuance-Alpha Capital Anstalt	3,504,205	168,670,959
3/13/20	New Issuance-Alpha Capital Anstalt	3,903,387	172,574,346
3/13/20	New Issuance-Robert Herskowitz	1,680,000	174,254,346
3/13/20	New Issuance-Robert Herskowitz 2011 Irrv TR	280,000	174,534,346
3/16/20	New Issuance-Alpha Capital Anstalt	3,852,572	178,386,918
3/16/20	Cancellation-Robert Herskowitz 2011 Irrv TR	(280,000)	178,106,918
3/16/20	New Issuance-Robert Herskowitz 2011 Irrv TR	420,000	178,526,918
3/18/20	New Issuance-Alpha Capital Anstalt	4,074,376	182,601,294
3/19/20	New Issuance-Robert Herskowitz	2,450,000	185,051,294
3/19/20	New Issuance-Mark Herskowitz	600,000	185,651,294
3/20/20	New Issuance-Alpha Capital Anstalt	5,060,718	190,712,012
3/24/20	New Issuance-Alpha Capital Anstalt	5,066,462	195,778,474
3/31/20	New Issuance-Alpha Capital Anstalt	4,014,359	199,792,833
4/1/20	New Issuance-LICGO Partners	5,250,000	205,042,833
4/2/20	New Issuance-Alpha Capital Anstalt	4,231,624	209,274,457
4/3/20	New Issuance-Robert Herskowitz	631,178	209,905,635
4/3/20	New Issuance-Chase Finance Inc Profit Sharing	1,767,298	211,672,933
4/3/20	New Issuance-Robert Herskowitz 2011 Irrv TR	879,477	212,552,410
4/7/20	New Issuance-Navesink	1,875,000	214,427,410
4/7/20	New Issuance-Alpha Capital Anstalt	2,480,103	216,907,513
4/7/20	New Issuance-Alpha Capital Anstalt	1,835,259	218,742,772
4/7/20	New Issuance-Gerald Hickson	1,500,000	220,242,772
4/8/20	New Issuance-Alpha Capital Anstalt	4,550,803	224,793,575
4/8/20	New Issuance-Alpha Capital Anstalt	4,828,006	229,621,581
4/13/20	New Issuance-Alpha Capital Anstalt	4,553,436	234,175,017
4/17/20	New Issuance-LICGO Partners	5,500,000	239,675,017
4/17/20	New Issuance-Chase Financing Inc	1,318,340	240,993,357
4/17/20	New Issuance-Chase Financing Inc Profit Sh.	4,830,548	245,823,905
4/20/20	New Issuance-Alpha Capital Anstalt	4,841,966	250,665,871
4/22/20	New Issuance-Alpha Capital Anstalt	3,756,851	254,422,722
4/22/20	New Issuance-Alpha Capital Anstalt	1,009,757	255,432,479
4/22/20	New Issuance-LICGO Partners	240,000	255,672,479
4/23/20	New Issuance-Alpha Capital Anstalt	4,873,000	260,545,479
5/8/20	New Issuance-Alpha Capital Anstalt	4,567,644	265,113,123
5/8/20	New Issuance-Kenneth J Schaefer	2,100,000	267,213,123
5/13/20	New Issuance-Alpha Capital Anstalt	4,523,162	271,736,285
5/18/20	New Issuance-Chase Financing Inc	2,837,500	274,573,785
5/18/20	New Issuance-Chase Financing Inc Profit Sh.	3,750,561	278,324,346
5/18/20	New Issuance-Sovereign Partners LLC	1,225,000	279,549,346
5/18/20	New Issuance-Sovereign Partners LLC	4,800,000	284,349,346
5/19/20	New Issuance-Mark Herskowitz	600,000	284,949,346
5/21/20	New Issuance-Alpha Capital Anstalt	4,532,376	289,481,722
5/22/20	New Issuance-Edward Feighan	2,040,000	291,521,722
5/28/20	New Issuance-Alpha Capital Anstalt	4,818,234	296,339,956
6/10/20	New Issuance-Alpha Capital Anstalt	4,283,652	300,623,608
7/7/20	New Issuance-Edward Feighan	2,040,000	302,663,608
7/21/20	New Issuance – Herskowitz	2,400,000	305,063,608
8/17/20	New Issuance-Alpha Capital Anstalt	5,026,179	310,089,787
8/19/20	New Issuance-Edward Feighan	945,000	311,034,787
8/24/20	New Issuance-Paradigm Capital Holdings	2,400,000	313,434,787
9/18/20	New Issuance-Alpha Capital Anstalt	5,070,154	318,504,941
10/5/2020	New Issuance-Alpha Capital Anstalt	5,087,744	

323,592,685

10/5/2020	New Issuance-Thomas Nelson	360,000	323,952,685
10/5/2020	New Issuance-JAN Stock Trust	180,000	324,132,685
10/5/2020	New Issuance-KEN Stock Trust	180,000	324,312,685
10/5/2020	New Issuance-Thomas Nelson	720,000	325,032,685
10/5/2020	New Issuance-JAN Stock Trust	360,000	325,392,685
10/5/2020	New Issuance-KEN Stock Trust	360,000	325,752,685
10/14/2020	New Issuance-Mark Herskowitz	600,000	326,352,685
10/19/2020	New Issuance-Alpha Capital Anstalt	5,672,593	332,025,278
11/10/2020	New Issuance-Mark Herskowitz	600,000	332,625,278
11/13/2020	New Issuance-Chase Financing Inc Profit Sh.	3,522,546	336,147,824
11/16/2020	New Issuance-Alpha Capital Anstalt	6,935,613	343,083,437
12/3/2020	New Issuance-LICGO Partners	1,765,000	344,848,437
12/3/2020	New Issuance-Alpha Capital Anstalt	1,478,481	346,326,918
12/3/2020	New Issuance-Alpha Capital Anstalt	1,842,714	348,169,632
12/3/2020	New Issuance-Alpha Capital Anstalt	1,572,161	349,741,793
12/15/2020	New Issuance-Alpha Capital Anstalt	1,453,926	351,195,719
12/15/2020	New Issuance-Alpha Capital Anstalt	1,255,770	352,451,489
12/15/2020	New Issuance-Alpha Capital Anstalt	1,195,971	353,647,460
12/15/2020	New Issuance-Alpha Capital Anstalt	848,123	354,495,583
01/12/2021	New Issuance- Thomas Nelson	360,000	354,855,583
01/12/2021	New Issuance- Ken Stock Trust	180,000	355,035,584
01/12/2021	New Issuance JAN Stock Trust	180,000	355,215,583
01/12/2021	New Issuance Navesink Device Initiatives	1,215,000	356,240,583
4/13/2021	New Issuance-Thomas Nelson	360,000	356,700,583
4/13/2021	New Issuance-JAN Stock Trust	180,000	356,880,583
4/13/2021	New Issuance-KEN Stock Trust	180,000	357,060,583

PREFERRED B STOCK

Date	Description	Change in Shares	Running Total
3/23/2011*	New Issuance-Centurion Credit Resources	1,000	1,000
7/16/19	New Issuance-LICGO Partners LLC	400	1,400
7/16/19	New Issuance-Sovereign Partners LLC	210	1,610
7/16/19	New Issuance-Paradigm Capital Holdings	130	1,740
7/16/19	New Issuance-Navesink Device Initiatives LLC	260	2,000
5/22/20	Conversion-Edward Feighan	(136)	1,864
7/7/20	Conversion-Edward Feighan	(136)	1,728
8/19/20	Conversion-Edward Feighan	(63)	1,665

(*) These shares were placed on Stop Transfer in 2016 due to criminal action against the parent company of the holder. In 2017 the Company's Board of Directors canceled these shares. The company is now in settlement discussions with the Receiver now that Centurion Credit Resources has been liquidated.

PREFERRED C STOCK

Date	Description	Change in Shares	Running Total
------	-------------	------------------	---------------

3/21/2016	New Issuance-Paradigm Capital	800	4,885
4/26/2016	New Issuance-LICGO Partners	1,050	5,935
4/26/2016	New Issuance-Paradigm Capital	325	6,260
5/17/2016	Conversion-Navesink Device	(125)	6,135
5/18/2016	New Issuance-LICGO Partners	300	6,435
5/18/2016	New Issuance-Paradigm Capital	50	6,485
6/27/2016	Conversion-Navesink Device	(125)	6,360
8/2/2016	Conversion-Navesink Device	(125)	6,235
4/19/2017	Conversion-Paradigm Capital	(80)	6,155
4/19/2017	New Issuance-LICGO Partners	157	6,312
5/10/2017	Conversion-Navesink Device	(125)	6,187
7/24/2017	Conversion-Navesink Device	(125)	6,062
7/24/2017	Conversion-Paradigm Capital	(295)	5,767
7/25/2017	New Issuance-LICGO Partners	196	5,963
9/28/2017	New Issuance-Gerald Hickson	300	6,263
10/23/2017	New Issuance-LICGO Partners	210	6,473
1/18/2018	New Issuance-LICGO Partners	210	6,683
5/11/2018	New Issuance-LICGO Partners	210	6,893
7/30/2018	Conversion-Navesink Device	(125)	6,768
7/30/2018	Conversion-Navesink Device	(125)	6,643
7/31/2018	New Issuance-LICGO Partners	500	7,143
7/31/2018	New Issuance-LICGO Partners	210	7,353
7/31/2018	New Issuance-Sovereign Partners LLC	105	7,458
1/2/2019	New Issuance-LICGO Partners	420	7,878
1/2/2019	New Issuance-Sovereign Partners LLC	140	8,018
5/8/19	New Issuance-LICGO Partners	420	8,438
5/8/19	New Issuance-Sovereign Partners LLC	140	8,578
7/16/19	New Issuance-LICGO Partners	210	8,788
7/16/19	New Issuance-Sovereign Partners LLC	70	8,858
10/11/19	New Issuance-LICGO Partners	210	9,068
10/11/19	New Issuance-Sovereign Partners LLC	105	9,173
12/31/19	New Issuance-LICGO Partners	210	9,383
12/31/19	New Issuance-Sovereign Partners LLC	70	9,453
4/1/20	Conversion-LICGO Partners LLC	(1,050)	8,403
4/7/20	Conversion-Navesink Device	(375)	8,028
4/7/20	Conversion-Gerald Hickson	(300)	7,728
4/17/20	Conversion-LICGO Partners LLC	(1,100)	6,628
4/22/20	New Issuance-LICGO Partners	210	6,838
4/22/20	New Issuance-Sovereign Partners LLC	70	6,908
5/18/20	Conversion-Sovereign Partners	(245)	6,663
7/21/20	New Issuance-LICGO Partners	210	6,873
7/21/20	New Issuance-Sovereign Partners LLC	70	6,943
10/5/2020	New Issuance-LICGO Partners	210	7,153
10/5/2020	New Issuance-Sovereign Partners LLC	70	7,223
12/3/2020	Conversion-LICGO Partners LLC	(353)	6,870
1/12/2021	New Issuance-LICGO Partners	210	7,080
1/12/2021	New Issuance-Sovereign Partners LLC	70	7,150
1/26/2021	Conversion-Navesink Device	(225)	6,925
4/13/2021	New Issuance-LICGO Partners	210	7,135
4/13/2021	New Issuance-Sovereign Partners LLC	70	7,205

PREFERRED D STOCK

<u>Date</u>	<u>Description</u>	<u>Change in Shares</u>	<u>Running Total</u>
12/31/2017	New Issuance-Sovereign Partners	40	40
7/31/2018	New Issuance-Navesink Device Initiatives	50	90
7/31/2018	New Issuance-Paradigm Capital	10	100
1/2/2019	New Issuance-Paradigm Capital	10	110
5/8/19	New Issuance-Paradigm Capital	10	120
5/8/19	New Issuance-Thomas Nelson	30	150
5/8/19	New Issuance-JAN Stock Trust	15	165
5/8/19	New Issuance-KEN Stock Trust	15	180
7/16/19	New Issuance-Paradigm Capital	10	190
10/11/19	New Issuance-Paradigm Capital	10	200
12/31/19	New Issuance-Paradigm Capital	10	210
4/22/20	New Issuance-Paradigm Capital	10	220
5/18/20	Conversion-Sovereign Partners	(40)	180
7/21/20	New Issuance-Paradigm Capital	10	190
8/24/20	Conversion-Paradigm Capital Holdings	(20)	170
10/5/2020	New Issuance-Paradigm Capital	10	180
1/12/2021	New Issuance-Paradigm Capital	10	190
4/13/2021	New Issuance-Paradigm Capital	10	200

PREFERRED E STOCK

<u>Date</u>	<u>Description</u>	<u>Change in Shares</u>	<u>Running Total</u>
1/18/2018	New Issuance-Robert Herskowitz	100,000	927,540
2/23/2018	Conversion-Robert Herskowitz	(100,000)	827,540
2/23/2018	Conversion-Chase Financing Inc Profit Sh.	(70,000)	757,540
4/16/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	857,540
5/11/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	957,540
6/11/2018	Conversion-Chase Financing Inc Profit Sh.	(75,000)	882,540
7/31/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	982,540
7/31/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	1,082,540
8/23/2018	Conversion-Chase Financing Inc Profit Sh.	(35,000)	1,047,540
8/23/2018	Conversion-Chase Financing	(50,000)	997,540
11/26/2018	Conversion-Chase Financing Inc Profit Sh.	(50,000)	947,540
11/26/2018	Conversion-Chase Financing Inc Profit Sh.	(100,000)	847,540
3/12/2019	Conversion-Chase Financing Inc Profit Sh.	(100,000)	747,540
5/8/19	New Issuance-Robert Herskowitz	175,000	922,540
5/8/19	New Issuance-Kenneth Schaefer	150,000	1,072,540
7/11/19	Conversion-Chase Financing Inc Profit Sh.	(200,000)	872,540
10/9/19	New Issuance-Chase Financing Inc Profit Sh.	300,000	1,172,540
10/29/19	Conversion-Chase Financing Inc Profit Sh.	(100,000)	1,072,540
3/10/20	New Issuance-Robert Herskowitz	120,000	1,192,540
3/10/20	New Issuance-Robert Herskowitz 2011 Irrv TR	30,000	1,222,540
3/13/20	Conversion-Robert Herskowitz	(120,000)	1,102,540
3/13/20	Conversion-Robert Herskowitz 2011 Irrv TR	(30,000)	1,072,540
3/19/20	Conversion-Robert Herskowitz	(175,000)	897,540
5/8/20	Conversion-Kenneth J Schaefer	(150,000)	747,540

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe any issuance of promissory notes, convertible notes or convertible debentures in the past two completed fiscal years and any subsequent interim period. See Table below.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Services, etc.)
03/29/2016	-	316,250.00	-	3/28/17	Convertible into common shares at \$.0678/share on due date	Alpha Capital Anstalt (1)	Loan Services
04/21/2016	-	460,005.75	-	4/20/17	Convertible into common shares at \$.0678/share on due date	Alpha Capital Anstalt (1)	Loan Services
05/13/2016	-	307,055.75	-	5/12/17	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
09/16/2016	-	402,505.75	-	9/15/17	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
12/31/2016	-	345,005.75	-	12/30/17	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
08/16/2017	26,000.00	345,005.75	-	8/15/18	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
11/06/2017	955,250.00	362,382.25	-	11/5/18	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
12/31/2017	987,000.00	402,505.75	-	12/30/18	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
05/22/2018	-	431,382.25	-	5/21/19	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
10/05/2018	-	230,005.75	-	10/4/19	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
03/22/2019	-	287,505.75	-	3/21/20	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
6/18/2019	-	250,010.00	-	6/17/2020	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
04/08/2016	-	345.00	-	4/7/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
04/14/2016	-	115.00	-	4/13/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
04/22/2016	-	57,523.00	-	4/21/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
05/26/2016	-	126.50	-	5/25/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
06/01/2016	-	172,615.00	-	5/31/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
06/02/2016	-	57,615.00	-	6/1/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
09/30/2016	-	28,750.00	-	9/29/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
09/30/2017	12,644	86,001.15	-	9/29/18	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
11/03/2017	27,600.00	27,600.00	-	11/2/18	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
01/18/2018	-	138.00	-	1/17/19	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
05/16/2018	28,750.00	28,750.00	-	5/15/19	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
03/31/2019	108,000.00	108,000.00	-	3/30/20	Inventory revolving line of credit	American Express (4)	Loan Services
12/16/2019	82,562.00	250,000.00	-	12/16/20	Inventory revolving line of credit	Reliant Fund 4)	Loan Services
2/27/2020	-	32,900.00	-	2/26/2021	Inventory revolving line of credit	West Coast Business (4)	Loan Services
4/22/2020	50,400.00	50,400.00	-	4/21/2021	Secured Promissory Note	Tom H. Nelson	Loan Services
3/12/2020	200,000.00	200,000.00	-	9/14/2020	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services
3/18/2020	250,000.00	250,000.00	-	9/18/2020	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services
3/23/2020	250,000.00	250,000.00	-	9/23/2020	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services
3/31/2020	300,000.00	300,000.00	-	9/30/2020	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services
4/7/2020	250,000.00	250,000.00	-	10/7/2020	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services
4/22/2020	250,000.00	250,000.00	-	10/7/2020	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services

9/14/2020	300,000.00	300,000.00	-	3/14/2021	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services
9/30/2020	300,000.00	300,000.00	-	3/30/2021	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services
10/01/2020	300,000.00	300,000.00	-	04/30/2021	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services
11/23/2020	250,000.00	250,000.00	-	6/23/2021	Secured Promissory Note	Alpha Capital Anstalt (1)	Loan Services
11/23/2020	100,000.00	100,000.00	-	11/23/2024	Secured Promissory Note	PNC Bank (4)	Loan Services
02/14/2021	250,000.00	250,000.00	-	02/14/2023	Secured Promissory Note	Ford Seeman (5)	Loan Services
03/24/2021	90,000.00	88,600.00	-	03/23/2022	Working Capital Debt	Kapitus Funding (4, 6)	Loan Services
03/24/2021	90,000.00	88,600.00	-	01/23/2022	Working Capital Debt	The Fund Works (4, 6)	Loan Services
04/01/2021	325,000.00	325,000.00	-	03/31/2023	Promissory Note	Keith Berman(4)	Loan Services

Use the space below to provide any additional details, including footnotes to the table above:

- (1) Alpha Capital Anstalt is an entity controlled by its Board of Directors. The managing directors are Konrad Ackerman and Nicole Feuerstein.
- (2) Chase Financing Inc. and Chase Financing Inc. Profit Sharing and 401K Plan are entities controlled by Robert Herskowitz.
- (3) Paradigm Capital Partners LLC, Navasink Device Initiatives LLC, Sovereign Partners LLC and LICGO Partners LLC are entities controlled, in equal parts by Alan Goddard and Michael Lichtenstein.
- (4) Loan/Note Secured by guarantee of Keith Berman, CEO. Mr. Berman has loaned monies and guaranteed loans to the company since 2006. Mr. Berman became CEO of the company in 2017. Through June 30, 2021 Mr. Berman has loaned, guaranteed or provided his American Express card for trade debt totaling in excess of \$900,000.
- (5) Ford Seeman is an individual lender and distributor of our products and is not an officer, director or affiliate of the company.
- (6) Kapitus and The Fund Works are cash flow lenders who collectively loaned the company \$180,000 in March 2021. Keith Berman, CEO guaranteed these loans.

Notes payable - Convertible	Date	Account	Amount	OID @ 15%	Total Investment
Note Payable - Alpha Capital Anstalt	04/21/2016	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 400,005.00	\$ 60,000.75	\$ 460,005.75
Note Payable - Alpha Capital Anstalt	05/13/2016	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 267,005.00	\$ 40,050.75	\$ 307,055.75
Note Payable - Alpha Capital Anstalt	09/16/2016	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 350,005.00	\$ 52,500.75	\$ 402,505.75
Note Payable - Alpha Capital Anstalt	12/23/2016	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 300,005.00	\$ 45,000.75	\$ 345,005.75
Note Payable - Alpha Capital Anstalt	08/16/2017	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 300,005.00	\$ 45,000.75	\$ 345,005.75
Note Payable - Alpha Capital Anstalt	11/06/2017	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 315,115.00	\$ 47,267.25	\$ 362,382.25
Note Payable - Alpha Capital Anstalt	05/22/2018	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 375,115.00	\$ 56,267.25	\$ 431,382.25
Note Payable - Alpha Capital Anstalt	10/05/2018	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 200,005.00	\$ 30,000.75	\$ 230,005.75
Note Payable - Alpha Capital Anstalt	10/05/2018	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 200,005.00	\$ 30,000.75	\$ 230,005.75
Note Payable - Alpha Capital Anstalt	6/18/2019	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 250,010.00	\$ 37,500.00	\$ 287,510.00
Notes payable - Secured Promissory	Date	Account	Amount	OID @ 15%	Total Investment
Note Payable - Alpha Capital Anstalt	3/12/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 200,000.00	\$ -	\$ 200,000.00
Note Payable - Alpha Capital Anstalt	3/18/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 250,000.00	\$ -	\$ 250,000.00
Note Payable - Alpha Capital Anstalt	3/23/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 250,000.00	\$ -	\$ 250,000.00
Note Payable - Alpha Capital Anstalt	3/31/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 300,000.00	\$ -	\$ 300,000.00
Note Payable - Alpha Capital Anstalt	4/7/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 250,000.00	\$ -	\$ 250,000.00

Note Payable - Alpha Capital Anstalt	4/7/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 250,000.00	\$ -	\$ 250,000.00
Note Payable - Alpha Capital Anstalt	9/14/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 300,000.00	\$ -	\$ 300,000.00
Note Payable - Alpha Capital Anstalt	9/30/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 300,000.00	\$ -	\$ 300,000.00
Note Payable - Alpha Capital Anstalt	10/01/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 300,000.00	\$ -	\$ 300,000.00
Note Payable - Alpha Capital Anstalt	11/23/2020	Notes payable - Note Payable - Alpha Capital Anstalt (1)	\$ 250,000.00	\$ -	\$ 250,000.00
Note Payable – Ford Seeman	02/14/2021	Notes payable - Note Payable – Ford Seeman (5)	\$ 250,000.00	\$ -	\$ 250,000.00
Note Payable – Keith Berman	04/01/2021	Notes payable - Note Payable – Keith Berman (4)	\$ 325,000.00	\$ -	\$ 325,000.00

- (1) Alpha Capital Anstalt is an entity controlled by its Board of Directors. The managing directors are Konrad Ackerman and Nicole Feuerstein.
- (2) Chase Financing Inc. and Chase Financing Inc. Profit Sharing and 401K Plan are entities controlled by Robert Herskowitz.
- (3) Paradigm Capital Partners LLC, Navasink Device Initiatives LLC, Sovereign Partners LLC and LICGO Partners LLC are entities controlled, in equal parts by Alan Goddard and Michael Lichtenstein.
- (4) Loan/Note Secured by guarantee of Keith Berman, CEO. Mr. Berman has loaned monies and guaranteed loans to the company since 2006. Mr. Berman became CEO of the company in 2017. Through June 30, 2021 Mr. Berman has loaned, guaranteed or provided his American Express card for trade debt totaling in excess of \$900,000 beginning in 2006..
- (5) Ford Seeman is an individual lender and distributor of our products and is not an officer, director or affiliate of the company.
- (6) Kapitus and The Fund Works are cash flow lenders who collectively loaned the company \$180,000 in March 2021. Keith Berman, CEO guaranteed these loans.

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Keith M. Berman
Title: CEO & CFO
Relationship to Issuer: Officer & Director

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Financial notes; and
- G. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. (“Annual Report,” “Quarterly Report” or “Interim Report”).

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

See documents attached hereto.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE COMPANY'S BUSINESS AND PRODUCTS

Overview

Decision Diagnostics Corp. is a necessary services worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose, the GenViro! Swift kit and meter a proprietary, patent pending technology for the identification of Covid-19 virions, the PetSure! glucose test strip for the glucose testing of dogs and cats, a test strip designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy market-leading meter, the GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system inclusive of the company's GenUltimate! 4Pets test strip and Advantage meter, for the testing of dogs, cats and horses. The company also has its GenUltimate! Sure, GenChoice!, GenUltimate TBG and GenUltimate! Precise test strips, products solely for off-shore sales (because no domestic market has developed). We also continued and completed work, in association with our international distributors, to secure the appropriate regulatory approvals which now allow for the manufacturing and out-sourcing of the 2021 2.0.1 version of our GenViro! Swift saliva kits for the aforementioned diagnostic detection of Covid-19 utilizing human saliva samples. The company has also completed and made available for sale in select international markets GenUltimate TBG a high precision product designed to provide highly accurate and precise glucose results utilizing the company's impedance technology (similar in nature to the GenViro! product) that corrects for an abundance or deficit of red blood cells in whole blood. Both GenViro! and GenUltimate TBG use highly specific sensor technology developed to test (at the present time) capillary blood and saliva in a human sample. Recently we have considered adding the TBG technology and meter to our GenUltimate! Precise product to extend its life-cycle. GenUltimate Precise is presently manufactured for our Russian Federation distributor.

Renewed International Focus

In the Fall of 2020 the company entered into a Definitive Agreement with a distributor for the sale of our GenUltimate! brand products and when available our GenViro! Swift kits in Central and South Asian countries including India, Malaysia, Indonesia and Singapore, and separate exclusive distributorships for the Russian Federation countries and the Ukraine. The company most recently executed an agreement for an exclusive distributorship covering most of the European Union countries (several EU member countries are also part of the looser Russian Federation of countries and will be serviced as a result of the regulatory approval through the EU). The Asian countries' distributor and the Russian Federation distributor will also carry our glucose testing products as well as our Covid-19 products when they become available. The EU distributor is currently carrying our GenViro! Covid-19 detection products, and has allowed their sales and marketing representative to market our glucose testing products using their same dealer network.

The EU and Russian Federation distributors have filed for approvals with Russian Federation regulators and with German and EU regulators (to represent our glucose products in the EU, Eastern Europe and Russia (with the GenViro! products to be piggy-backed on the EU work now in progress). The EU distributor filed with German (their domicile) regulators, Bundesinstitut Fur Arzneimittel und Medizinprodukte (also colloquially known as BfArM), the German equivalent of the U.S. FDA. The registration under emergency provisions (January 2021 update) was for the marketing of our GenViro! products. In addition European Union CE approval has been obtained for GenViro!. The technical registration (the equivalent of FDA allowance) was approved by the German BfArM in early May 2021. International regulatory approvals are the sole responsibility of the company's distributors. The company's role is to provide the proprietary documentation, engineering documents, and testing information to the distributor for their submissions and prosecution and defense of their applications. As for the testing, our German distribution partner has asked us to conform all testing to the January 2021 "Minimum criteria for SARS-CoV-2 antigen tests: Antigen rapid test."

The BfArM approval:

AT921/21 GenViro!	Pharma Tech Solutions Inc.	Westlake Village	US	Pedima International GmbH	Düsseldorf DE	Details	POC (mitGerät)	86,84	71,10 - 95,00	97,92	87,50 - 99,80
-------------------	----------------------------	------------------	----	---------------------------	---------------	---------	----------------	-------	---------------	-------	---------------

The company's exclusive EU based distributor has also provided the company with an initial purchase order for over 5 million GenViro! Swift test kits, verification test kits, and a corresponding number of meters. In addition, through its distributor, the company has been provided an opportunity to sell its kits to operators of Formula One car racing events. We have not decided whether to accept this opportunity, as we determine the reason for a major pharma company recently ending their participation. As registrants with the U.S. FDA and with the international ISO we cannot risk a chance that those that administer the tests at the Formula One events do not meet the required professional qualifications required to administer the Covid-19 test kits. Also the Formula One group requires a change to the "kit" packaging, requiring bulk packaging (100 kits per Master case). Given the volume of kits involved at a Formula One event a change in packaging could create bottlenecks in the production process. Nonetheless we are going to move forward with a plan that will allow us to provide kits for an upcoming race on October 1, and then thereafter, because we believe that Formula One races could potentially provide a testing foundation for European Football (out of doors) and European basketball and hockey matches (indoors).

In April 2021 the company became aware that certain of the electronic components that make up its GenUltimate TBG and GenViro! Swift meters were in a then current critical short supply situation owing to certain negative outgrowths of the Covid-19 pandemic. These critical shortages have only recently eased slightly, allowing the company to GenViro! Swift kits. There are not enough available quantities (yet) of components (particularly impedance chips) to manufacture GenViro! Swift and GenUltimate TBG meters in quantities for the wholesale marketplace, where dealers but from distributors. However, there will be enough meters available to service all of Pedima's direct sales. Recently the company has asked Pedima to also ship directly to Baltic states (members of the EU and Russian Federation). In addition critical materials shortages often lead to longer lead times from suppliers and suppliers of our contract manufacturer, higher prices or both. This issue, although serious and worldwide, has not slowed down the sales efforts for GenViro! Swift of our EU distributor Pedima International who continues to sell and bank orders. The proposal from Formula One is an example but not the only example. However, the critical materials shortage has created issues for our contract manufacturer The Bio.

<https://www.cnbc.com/2021/05/07/chip-shortage-is-starting-to-have-major-real-world-consequences.html>

<https://www.vox.com/recode/2021/8/5/22611031/chip-shortage-cars-electronics-automakers-gm-tesla-playstation-xbox>

First deliveries of GeViro! Swift kits and meters were made early in July 2021. Shipments in July included shipments of GenViro! Swift meters making use of Version 1.1.7 software and database. All shipments in August and later will have GenViro! Swift meters making use of GenViro! Swift meter Version 2.0.1. Revenues from sales made by our EU distributor Padima International will be accrued in 3Q and 4Q 2021.

We are concentrating new sales agreements of our brands in international markets in order to be in a position to sell GenViro! Swift Kits now that international regulatory approval from a renowned regulatory organization has been obtained. The company has developed and manufactured products for international distribution where a large number of glucometers are in use running test strips from legacy manufacturers. This is our long standing practice where there is no domestic or North American markets for the same products. We have also begun adding distribution in Central America and Mexico, and expect to conclude discussions with Canadian and African country representatives. Brazil also remains a significant target for the company.

In mid-February 2020 we were first advised of the large outbreak of Coronavirus in Korea, and in particular in the city of Daegu, Korea. Daegu is the Korean city where since 2016 the company's manufacturing facility and patient trials hospital and product testing facilities are located. At first it was difficult to receive information as to the severity of the virus (other than what we could see on TV) and how it was affecting the company's facility in Daegu, and at the Catholic missionary hospital also located there where several of our donor (clinical) studies were conducted. Over a year later, our own domestic coronavirus issues are on-going while significant portions of Europe are undergoing what is called the Fourth Wave of Covid (Delta and Lambda), and experts in this country believe this wave may also occur or is occurring here despite increased vaccinations.

As a result of this pandemic, we learned for the first time the use of words like "lock down" and "lock up." We have subsequently recovered from these problems that the pandemic virus caused to our manufacturing and testing activities in South Korea. It was explained in our 2020 Annual Report that even though our manufacturing partner, The Bio, had remained open for business after the February-March 2020 Covid troubles in Korea, some of their suppliers were still suffering from problems that the pandemic caused. While our legacy product sales throughout 2020 were strong, to a certain degree this resulted from our shipping product from existing inventory. Subsequently and more recently the Covid-19 pandemic has had effect on manufacturing of certain

OTC Markets Group Inc.

OTC Pink Basic Disclosure Guidelines (v2.0 February 2019)

Page 18 of 38

semi-conductor chips worldwide, causing large bottlenecks. Our performance in 2020 reflected the impact of the Covid-19 lockdowns both in the USA and Korea, and our sales and the sales of our major USA distributors were affected, not only by the inability to receive suitable quantities of newly manufactured product from our Korean partner who, if anything was plagued even more than we have been, but also from the economic impact in the U.S. where several of our distributors had major cash flow issues of their own and either curtailed ordering or were put on “cash in advance” terms, all of which affected sales. Throughout FY2020 we have been still dealing with slower payments, particularly from several distributors, including one of our largest distributors who could not meet “cash on demands” terms.

As this Coronavirus spread during the early winter months of 2020, we asked our partner The Bio to look into whether some of our diabetic detection and management technologies could be put to use to potentially develop a coronavirus diagnostic test. In particular our GenUltimate TBG product makes use of a technology known as Electrochemical Impedance Spectroscopy (impedance or EIS) to detect and quickly count red blood cells present in a human (or animal) sample. The EIS process employed by the company in its GenUltimate TBG product counts the red blood cells in a sample in less than 4 seconds and then uses this “count” to statistically adjust the glucose test run by the GenUltimate product to correct for an over or under abundance of these red cells, a major interference issue in all glucose testing. Using a number of publicly available sources including white papers and dialogue and graphics available on the Internet, we concluded that we could use this same type of proprietary technology that had been perfected and was being used for our glucose testing technology to “count” other particles in a human (or animal) sample -- including virus particles. Subsequently similar products and technologies developed at Johns Hopkins and Monash University (in Australia), as well as an influencing paper out of the Russian Federation have proven us and our technology to be well ahead of the technology curve.

We had decided that if such a test methodology proved workable it would be worthwhile from a humanitarian standpoint to use some of (later, most of) our limited resources at least to try to develop such a test (“count”) method. Shortly thereafter we received various technical paper citations from The Bio and our domestic consultant, describing certain technical papers written from 2006 through 2015 where the researchers and scientists discussed their research in detail and their ability to use a method called impedance (EIS) to identify and classify certain (now familiar) classes of virus. We also received from the Bio an initial development schedule for our long standing product. Then subsequently similar papers, one in particular only a few months old, became available from certain Russian scientists, as well as authoritative papers that are/were posted on the U.S. NIH web site. In addition, a similar product to our GenViro! that first appeared in May 2021, uses EIS technology and a product from Canada first discussed in early 2021 also makes use of a technology similar to EIS. We have learned that although EIS was not a household name, nonetheless there were numerous applications both within and outside of healthcare where this technology was and is being used. Regarding the references provided by our Korean partner, these papers described their impedance (EIS) methodologies for the identification of various influenza and influenza like virus including the H5N1 virus. The papers also included sample data sets. From these papers our highly regarded and highly credentialed technical consultant became optimistic that we could adapt critical parts of our GenUltimate TBG impedance technology to work as a diagnostic to identify Covid-19, and do so reliably.

<https://duckduckgo.com/?q=electrical+impedance+spectroscopy+medical+products&t=newext&atb=v232-l&iax=images&ia=images>

In the papers we initially relied upon, it was described that researchers designed and built a bench level chemistry methodology and their version of an identification device, and then performed tests on patient samples. In all cases the number of patients (subjects) tested was statistically significant. The importance of these publications indicated that a testing device and chemistry method using EIS (better described as an energy pulse with traits somewhat similar to an electric current and a radio wave pulse), could be created in relatively short order to measure the presence or absence of such a virus (of interest) such as influenza (types a & b) and H1N1 influenza, as well as the closest “relatives” of Covid-19, the earlier (2006-2008) SARS virus and the MERS (2012-2015), and through our own development methodology, Covid-19.

The company’s GenUltimate TBG product makes use of impedance (EIS) technology to measure the number of red blood cells in a patient’s blood sample, information relevant to a glucose measurement in that person. Mr. Berman, the company’s CEO, became convinced that a similarly configured device could be built for the detection of Covid-19. During the development of the company’s GenViro! Swift kit, Mr. Berman became further convinced that the GenUltimate TBG impedance “module” should be moved to the new GenViro! Swift product, primarily because GenViro! blood-based methodology appeared to need the same red blood cell (hematocrit) correction required and present in the company’s GenUltimate! TBG product.

The company promptly consulted with an expert in sensitive electrode technology (and holder or collaborator in numerous patents published in parallel fields) to assist in the design of a testing method and device for the detection of Covid-19.

The company also engaged FDA practice counsel who was already familiar with the company’s diabetic products and technology to prepare GenViro! for submission for emergency use authorization (EUA) by the FDA. This initial contact was made as

February transitioned into March 2020, around the time that the FDA's eased guidance for EUA, first published on February 27, 2020. A subsequent further easing of FDA past policy appeared in a March 16, 2020 guidance policy. All of the changes and/or addition to guidelines relate to the granting of emergency use of Covid-19 testing products. Additional guidelines have been published by the FDA in May 2020 and July 2020, and in September and October 2020 the FDA added further emergency guidelines. However, as of this writing, there is still no FDA Guidance that specifically addresses a product based on our EIS technology.


In January 2021, German medical device regulators further refined testing and test presentation guidelines to reflect testing methods to direct detection devices (direct fast antigen methods). Certain of these publications eased the company's product development and testing tasks, while others have made it more difficult. As of this writing, there are no FDA guidelines published for direct antigen methods for at-home testing. However, German regulators (BfArM) that are the main regulator for the EU have provided guidance, which the company's GenViro! product meets. Thus far, the FDA has limited their guidelines for emergency at-home use to older (and slower) PCR methods. There are however guidelines for at home testing in Europe (and Russian Federation countries) which the company intends to utilize. The company's regulatory approved version of GenViro! Swift is a Point of Care product, meaning that the test is administered by trained professionals and para-professionals, rather than being self-administered.

Mr. Berman set down guidelines for creating the company's Covid-19 testing devices. His project scope initially mandated that the test method must be measured on a variation of the company's existing Precise or Advantage glucometer mold and electronics, subject to changes to these electronics in the meter, and the differences in test strip size and configuration, to reflect the higher powered electrodes required for virus detection using small (fingertip) samples of whole blood. Subsequently, the company also added testing using saliva to its kit configurations. In addition, the resulting chemistry would necessarily run using a small sample size of a patient's whole blood taken from a finger prick (also known as capillary blood) or a small (neonate sized) blood collection device or from saliva taken from a capture cylinder. Both the blood and saliva methods, as outlined in the published papers drawn on by the company, would require dilution for the Covid measurement to occur. It was established in advanced testing that 1-2 microliters of fluid (a small drop on a fingertip for blood) or a small amount {two spits} in a saliva capture cylinder, were needed to perform the test and provide a result in one minute or less (later redefined in two iterations to its current 10.5 seconds or less, with testing currently underway (for GenViro! version 2.0.1) to lower the actual testing to 8 seconds), with the potential 8 second test a second generation product entry. The company built the product so that it could function with at least a 95% specificity (the newest FDA guidelines), and 97% specificity (in the German regulator guidelines). As seen above with the BfArM regulatory listing, GenViro! Swift performs at 97%+ specificity.

Three alternative designs for the proposed blood-based testing kits were provided in writing and given to the company for evaluation in early March. Two of the designs came from the company's U.S. based consultant, and the third design from The Bio in Korea. The chosen method bears the trademark and the trade name GenViro! Swift.

The company then evaluated the designs, keeping in mind the desired specifications of the DECN CEO who was also the product Program Director, which included: (1) availability of components without wait time (off the shelf availability), (2) time to market (assuming FDA EUA and/or European BfArM approval or CE), whether the chosen method was applicable to use in point of care and/or at-home self-test environments, (3) time of assay from commencement of test and until result, (4) size of the blood (and shortly thereafter saliva samples after the Rutgers University and the University of Illinois methods were discussed in the literature in early April 2020), and (5) the use of the resulting product should be of a design understandable to a private at-home user even though the first generation product would necessarily be operated by testing professionals, and finally, (6) cost to produce. Given the company's experience in working with biosensors and with electrode technology, the design review process took less time than originally expected. At the end of this technology review and choice process, the company chose to produce the product shown in the illustrations below.

Product Design Chosen



The design above makes use of a virus antigen approach favored by some of the competitive companies in the Covid-19 testing field, but, as it turns out, not a preferred method at the FDA which favors PCR, a 35+ year old standard. The major difference is that the approach used by the company in its GenViro! Swift product allows for swift (10.5 seconds or less, with a 8.0 second method within reach), results using a minimum of blood from either a finger prick, a neonate blood collection device, or a small amount of saliva from a human subject. All work commenced on the product specification chosen by Mr. Berman with components such as the platinum electrodes, platinum carbon paste, industrial films (several types) to make the biosensor, and potentially a new impedance chip for the meter. Prototypes of the test strip and the metering device were employed and test strips for final investigational testing were delivered to the company in August 2020. No changes have been made to the initial test strip since the delivery of final testing test strips were delivered in August 2020. Additional test strips in somewhat larger quantity were delivered in late August 2020, late September 2020 and multiple times subsequent to these dates. In addition while the FDA requires a minimum of the testing of 30 positive samples and 75 known negative samples, all subsequently verified using PCR methodology, the company has set multiples of these testing quantities and has set preliminary testing (to set the testing rules) and final testing to apply the rules. For the German BfArM registration the company used a total of 475 samples, 350 samples and 295 samples, respectively.

For FDA EUA filing and the seeking of a Pre-EUA by the FDA, the company first filed an application for its Professional use version of its GenViro! Covid-19 test kit on April 3, 2020. We received PEUA designation from the FDA on April 4. Conversations with FDA review staff for the point of care testing of finger-tip blood from human subjects began on April 14th. The company then filed a second EUA application with the FDA on May 1, 2020. This application was for the individual use GenViro! test kits, again using a finger-tip blood sample. We received PEUA designation from the FDA on May 2, 2020. As of August 10, 2021, the FDA has yet to publish guidelines for at-home use of antigen based diagnostic methods.

Our GenViro! test kit has been designed to work in either an at-home or point of care environment, the PFU, “how-to” video, and user’s guides have been written to instruct both professionals and at-home users in multiple languages. The GenViro! test kit is capable of achieving a desired test result whether the human sample is blood, saliva or urine. No changes have been made to the sensor that takes the virus reading. Presently clinical work has taken place using human saliva and capillary blood. No work has yet been completed using urine as a sample source. The company does plan to begin testing of venous blood (distinguished from capillary blood) samples gathered from patients at some point in 2022. Thus our switch from the original finger-tip blood test readings to saliva readings was seamless, only requiring slightly different meter software and meter database (gathered from human testing) -- and a lot of testing.

Along with this testing (as this Quarterly Report is filed) the German (EU) requirements (and thus the Russian follow-on) are listed below:

Specificity: “Examination of at least 100 asymptomatic persons without a specific risk of exposure with the SARS-CoV-2 rapid antigen test; Clarification of any reactive samples using PCR.”
Rapid antigen test criterion: Specificity >97%

Sensitivity: “Criterion antigen rapid test: >80% of unselected PCR-positive samples positive in the SARS-CoV-2 antigen rapid test” Rapid antigen test criteria: **Sensitivity >80%**

According to the Paul Erlich Institute in Germany, there is currently no international standard available to determine an analytical minimum sensitivity for SARS-CoV-RNA or for SARS-CoV-2 antigen. The >80% criteria appears to have been chosen by the German authorities. It is not known if the U.S. FDA will accept this standard. However our plans for the FDA registration are different. Testing has shown that GenViro! exceeds this criteria described in the January 2021 Paul Erlich Institute paper.

We continue to explore potential ways to fast track our GenViro! test kit in the U.S. and have had discussions with a laboratory in Massachusetts for a laboratory method, an FDA fast track to EUA approval. This Laboratory Method FDA short form requires the laboratory to provide verification for their own EUA use. Laboratories are allowed to sell their Laboratory Method products prior to filing for EUA. In addition we did recently ask our EU distributor to manage an application for GenViro! to and through the World Health Organization.

GenViro! distribution through international venues are subject to local rather than US regulations and therefore may use the following types of tests, if allowed by country and regional regulations and guidelines, in considering whether to grant approval for use in those countries or regions:

- Tests authorized through the FDA’s EUA process
- Tests listed on the World Health Organization Emergency Use Listing (EUL)
- Tests approved by internationally recognized regulatory authorities (eg, CE-Marking, German BfArM)

- Tests developed by a laboratory or tests validated by a laboratory
- Tests authorized by the state where the laboratory is located

The company has completed the packaging and package inserts for four versions of its GenViro! Product, GenViro! Point of Care, GenViro! At-Home use, GenViro! Saliva Point of Care, and GenViro! International in English, Spanish, French, German and Russian languages for Saliva. We have also completed the GenViro meter User Guide in the same languages. The company has completed the UPC clearing house GS-1 assigning UPC identifiers to these four products, and then most recently a bulk package 5th version of product packaging, all of which will be produced for testing and registration purposes as “Investigational Use” products, with the “Investigational Use” stickers removed as each version of the company’s GenViro! products receive their respective regulatory emergency approvals. An example is given below for illustrative purposes only. The kit shown below was used in the second and third testing studies. Since the studies were successful, this kit is expected to be sold commercially in European markets. The company’s (revised) retail kits will include a test strip, lancets and a neonate sized blood collection device (blood) or saliva cylinders (saliva) an interface sleeve to cut down human fluid contamination at the meter, and the meter itself.

http://www.decisiondiagnostics.co/assets/vids/GenViro_eng.mov



GenViro! Swift kits are not yet available for sale in the USA or Puerto Rico.

Late in 2Q 2020 the company filed two Provisional Patents with the U.S. Patent and Trademark Office for the protection of its impedance (EIS) based technologies employed in its GenViro! Swift and GenUltimate TBG products. The company has subsequently engaged counsel to file the final patent application(s). Both of the GenViro! Swift and GenUltimate TBG products make use of the company’s proprietary impedance technology.

Regarding additional product development, the company has completed advanced development work and third party testing of its GenUltimate! TBG test strip and TGB Precise meter. Substantial testing for this product has been completed in Korea and parallel testing has been done by the company’s U.S. consultants. Further, the company’s EU distributor’s US agent has entered into an agreement with the company to sell the GenUltimate TBG product in the EU. In 2019, in association with the company’s advanced development engineers, company CEO Keith Berman asked for a change to the engineering foundation of the GenUltimate! TBG system to work in an identical manner with the company’s GenUltimate test strip and with the (Platinum) Lifescan Ultra meters and test strips that the company’s GenUltimate product has become an alternative methodology to.

The enhanced version of GenUltimate! is named GenUltimate! Premier and is expected go on sale in certain international markets commercially later in 2021. We are currently in the process of building an international distribution network for this product. At the moment our Korean partner is involved primarily with our GenViro! Swift kits. GenUltimate! Premier! owing to its near analyzer level precision (in a handheld device) will carry a substantially higher MSRP, Big Box, and wholesale pricing. The company will continue to sell its GenUltimate! product in existing markets.



As off-shore products GenUltimate! Sure and GenUltimate! Precise are test strips that run on four existing Platinum/Lifescan legacy meters, and will only be sold in select international markets, primarily in the Russian Federation. There are no USA markets for either test strip and none is expected to develop. The International roll-out decisions were to choose those markets where the products will not encounter certain performance criteria issues created by the legacy metering platforms that the GenUltimate! Sure and GenUltimate! Precise test strips run on. The GenUltimate! Sure product in particular, although sharing many similarities with the company's GenUltimate! product, does not have the capability for future improvement or upgrade and as a result is viewed in the market and by DECEN as a small niche product, subject to cancellation at any time. Thus, most of the company's attention for International markets will be focused on GenUltimate! Precise. The GenUltimate! Precise product has more potential in that it is capable of having portions of the company's TBG technology added-on at a later date. Thus, the conclusion was that having two finished products is better than having no product at all, so the company will continue to perform compatibility testing with the family of legacy meters as we solidify our relationship with our Russian Federation and Eastern European distributor -- who have emerged from a long quarantine (lock-down).

Resources permitting, we intend to register the company's GenChoice! and GenUltimate! TBG products in the EU, because these products do meet ISO guidelines without further development. The GenUltimate! TBG meter, which will undergo 510K prosecution for its metering system, is next up of our diabetes related products for FDA clearance. The test strip, a close relative of the company's GenUltimate! test strip, is already FDA cleared. The company has contracted with the same expert organization that wrote the 510K document and a credentialed IRB who completed the GenChoice! clinical trial data and who will follow the same clearance path for the GenUltimate! TBG system. But as stated, both are resource depending products.

The History of our Current Business Foundation

Our subsidiaries, Pharma Tech Solutions, Inc., PDA Services, Inc. and PharmaTech Sensor Development Corp. operate in several healthcare products channels. In addition our subsidiary Decision IT Corp. engages in the acquisition and holding of Intellectual Property including Patents and Trademarks and specialty manufacturing equipment acquired for our Korean contract manufacturer of our GenUltimate! as well as our GenSure! and GenChoice! products. Our newest subsidiary Pharmatech Sensor Development Corp. manages our investment in specialty manufacturing machinery and testing laboratories, as well as an inventory credit line to finance inventory purchases of our GenUltimate! and PetSure! products. The company has endeavored to expand the credit line for the management of our GenChoice! and GenUltimate! TBG products. The company has discontinued its earlier GenStrip 50 product and ended the selling of the last of the inventory in November 2016. All of the GenStrip 50 test strips have subsequently reached expiration dates.

In March 2017 the company was approached by its Korean partner, The Bio Co., Ltd to design and fund a new product which the company calls GenUltimate! TBG. This product represents a major improvement in diabetic glucose monitoring. The GenUltimate! TBG system will be the first of its kind +/- 8% system. The latest ISO (2015) and FDA (2016) guidelines call for glucose monitoring systems to meet a +/- 15% standard, whereby the meter and strip must be within +/- 15% of a reference method in repeated testings 95% of the time. GenUltimate! and GenChoice! are +/- 15% test strips, with GenChoice! perhaps a little bit better, but in each case 97+% of the time in repeated samplings. GenUltimate! TBG is designed to meet the written standards of the ISO and FDA at +/- 8%, 97% of the time – effectively setting a new standard. The company has been funding the development of this system product since 2017, as well as a test strip only derivative version for use with a legacy meter sold overseas. In October 2018 the company implemented a strategic change to its development and manufacturing processes whereby we standardized around two technology foundations, our GenUltimate! technology and our GenChoice! technology. Our PetSure! was the first marketable product to make use of the GenChoice! technology foundation, and is currently selling successfully in pet testing channels in the USA, Canada and the EU. The agent for our EU distributor has contracted with the company to market GenChoice! in the EU. GenUltimate! TBG is the first enhancement of our GenUltimate! technology foundation. The company believes that these changes in our product development processes will lead to quicker to market products and streamlined and less costly manufacturing processes.



*Not for Sale in the US or Puerto Rico

As of this writing, GenUltimate! Precis and GenChoice! products are not available for sale in the U.S. or Puerto Rico.

Historical Discussion

Shasta Technologies LLC, the original specifications provider of GenStrip, had an extremely difficult relationship with the US FDA and was the subject of a detailed and damning FDA (Enforcement) Warning Letter on April 8, 2014, and when they refused to respond to this Warning Letter in an expected fashion, the FDA then broadcast a worldwide Safety Notice on April 29, 2014, the FDA version of the Death Penalty. This second letter effectively ended Shasta's ability to be a product design specifier and manufacturer, due to a total lack of regulatory adherence in the highly regulated medical device industry. It is confusing to consider what Shasta could have possibly been thinking. The company's acquisition of Genstrip (now GenUltimate!) was fortuitous in its timing given the finality and outcome of Shasta Technologies' fatal troubles with the FDA. Shasta contested our acquisition and took other legal steps against their FDA lawyer and in retaliation against the company. During the efficacy of these litigations we had success in the courts. In December 2018 we received a grant of a judgment against Shasta for \$3.6 million. We perfected this judgment in California, Pennsylvania, Oregon (Shasta's domicile) and Minnesota. As we began levy against Shasta we accepted their offer of Settlement. As a result of this Settlement we were able to value our acquisition of GenStrip under our 2014 Agreement. A substantial gain occurred and is fully described and carries over to this financial report.

The worldwide market for at-home blood glucose testing is an estimated \$17.6 billion as of 2018, inclusive of the 2013 and 2016 changes to the Federal Medicare programs which gutted almost one-third of the U.S. market. The market is expected to have grown past \$20.0 billion worldwide by the close of 2020, even in the face of the Covid-19 pandemic. The current GenUltimate! competes directly with one of the largest worldwide platform manufacturers the venerable Platinum (formerly Johnson & Johnson) Lifescan Inc. Ultra legacy product. J&J, which had owned Lifescan for more than 25 years, sold its Lifescan division and its venerable products to Platinum, a private equity firm. GenUltimate! (and the earlier GenStrip 50) were developed for use with the Lifescan OneTouch Ultra legacy system for at-home blood glucose testing, a system currently used daily by approximately 2.5 million diabetes afflicted Americans and 5.8 million diabetics world-wide. GenUltimate! competes in the overall at-home testing market by offering an economical solution to former users of the legacy platform provider's product. The company's GenUltimate! product is a much improved version. Our business model is unique to this market channel as our major business focus is directed toward diabetics who have attempted a change of their glucose monitoring platforms (systems) or those currently using the Lifescan legacy products but are dealing with escalating prices and lower (if any) insurance reimbursements. At the time of the introduction of GenStrip in March 2013, Lifescan controlled just under 40% of this market and 100% of its own Lifescan, Inc. OneTouch Ultra market. Their overall market share has since dropped below 30%. In October 2018 Lifescan, Inc. was sold to a large California based private equity firm in an asset sale arrangement. This event gave impetus to the changes we have made to our GenUltimate! TBG system, the first and only evolutionary enhancement to be offered to the Lifescan Ultra family of products still in use by over 4 million diabetics worldwide (see Litigation section).

Lifescan Inc., until October 2018 the diabetes testing division of Johnson & Johnson, sued the company in three separate suits, all in Federal court, beginning in September 2011. These suits proved costly in that their intended purpose appeared to be part of a plan to keep the Genstrip product off of retail market shelves. Until these suits were settled in May 2016, the company's marketing abilities were severely limited. In fact, even as of this writing, the company faces market obstacles brought about by the original litigation with Lifescan, Inc. However, it should be noted that Johnson & Johnson announced in January 2018 that their entire diabetic business (three divisions, multiple products) had been put up for sale, and offers for some or all of their businesses had been received. The sale closed in October 2018 with the completion of an asset sale to a large California based private equity firm, Platinum Private Equity.

The settlements we did achieve with J&J provided a hard-fought victory for the company, particularly since in 2015 Shasta had admitted to patent infringements of all three J&J diabetic medical device patents that were being adjudicated. We settled these lawsuits in a novel manner, where Johnson & Johnson paid the company a settlement amount in cash, in those lawsuits where the

company was a defendant, a rarity in matters where the Plaintiff (J&J) had initiated the strike suit in the first place. J&J, as a part of the settlement, also granted the company licenses to three J&J patents (including one patent that J&J subsequently lost as a result of 3rd party prosecution by the company, through final action by the US Supreme Court), the larger value gained from this 5-year legal battle. In March 2016, prior to its settlement, the company's Pharma Tech Solutions, Inc. and Decision IT Corp. subsidiaries brought suit against Johnson & Johnson and Lifescan, Inc. in Nevada Federal court for patent infringement, the company alleging that Lifescan, Inc.'s OneTouch Ultra product was and had been infringing both of the company's patents. In March 2017, after a protracted battle with J&J where they tried to invalidate the company's lawsuit, the court in a major ruling agreed that the company will be allowed to move forward (a major victory so early in the suit) and will also be allowed to allege the Doctrine of Equivalents, a legal doctrine that would preclude J&J from twisting words through its pleadings and expert reports to escape justice. In April 2016 the company amended its original suit to include allegations under the Doctrine of Equivalents.

Further, in January 2016 the US Supreme Court ruled that the Doctrine of Laches, a defense used by many Defendants in patent infringement suits could no longer be used. This ruling further deprived J&J of one of its most important defenses against the company's current patent infringement claims. All of this action did not dissuade the Nevada District Court trial judge from granting J&J a Motion for Summary Judgment in October 2018. As a result of this ruling, the company filed an appeal to the U.S. Court of Appeals for the Federal Circuit ("Federal Circuit court") in Washington, DC (the patent court). The company's appeal was ruled against by the Federal Circuit court in 4Q 2019. The company, with many other irons in the fire, decided not to avail ourselves of further expensive and resource depleting appeal, thus ending this litigation.

The Current Business

On September 26, 2020 the company entered the international Covid-19 testing market by launching its GenViro! Swift kits in select international settings. Just prior to this product launch the company entered into a distribution agreement with a distributor with access to several Asian markets, including India, Malaysia and Indonesia. Subsequently the company has entered into distribution agreements with distributors in the European Union and Russian Federation. The company currently has almost 50 countries covered by existing distribution agreements.

The first of the company's commercial GenViro! Swift products will be its saliva based test kits. The diagnostic components (meter and test strip) of the saliva-based method are identical to the company's blood-based method. Measurement is taken by a test strip of a human fluid (saliva) collected from a walk-in patient, the fluid is first diluted, then mixed and stirred, and an impedance value is derived. This impedance value determines whether the patient is either positive or negative the Covid-19 virus. If the reading is incomplete, the human sample is re-run using the company's Covid-19 verification kit. In developing the saliva method it became clear that worldwide regulatory bodies, including the U.S. FDA., the EU (German) BfArM, and the WHO appeared to be more favorably disposed to saliva based methods.

Saliva as a testing medium has become a preferred medium by the regulators due to the fact that regulatory guidance for blood based methods is not prevalent and the saliva based methods are non-invasive. It is unknown what size the Covid-19 testing market will eventually encompass, but given the severity of the worldwide pandemic (primarily outside of the USA) and now beginning a 5TH wave, the company is developing screening tests for mass distribution initially in a point of care environment, in the hope to be in a position to make a significant market entry, although we recognize increasing competition from several companies with significantly greater resources than we have or can realistically expect to secure access to. To assist in achievement of our goals we have recently developed bulk packaging for our GenViro! Swift kits, containing 100 each of our test strips, saliva collection devices, along with our extension sleeves and diluent.

One study shows anecdotal worldwide revenue for Covid-19 testing products of approximately \$15 billion (as of July 2020) and growing dramatically. Another study shows the market for Covid-19 related diagnostics products growing to over \$100 billion in the next several years, peaking in 2025. Both of these studies were completed prior to the Covid Delta Variant became prevalent. The company continues to believe there will be substantial worldwide demand for its GenViro! Swift kits even in an environment where Covid-19 vaccines are available.

The company's major current diabetes testing market focus is on large on-line retailers such as Amazon and Walmart, as well as pharmacy chains, grocery chains with in-store pharmacies, large all-purpose retailers with in-store pharmacies, and group buying and chain pharmacy organizations, and for its pet testing products, on-line sales and chain pet supply stores and retail pet outlets.

The company has also implemented a successful "direct to diabetic" business model and has (independently or along with our distributors) executed on-line agreements with several of the largest retail chains, diabetic supply co-operatives, group purchasing

organizations, as well as on-line mass merchandisers such as Amazon.com, eBay, Walmart, Sears, and approximately 1050 other on-line cooperatives and product aggregators.

In March 2015 we first acquired special intellectual property and specialty manufacturing equipment which served our business interests then and into the future. Beginning in 2014 and 2015 we turned to Alpha Capital Anstalt (“Alpha”), Navesink Device Initiatives, Sovereign Partners and Licgo Partners, whereby these organizations either purchased an 18-month 15% OID derivative instruments or Preferred C and Preferred D stock units, to facilitate the acquisition of intellectual property or manufacturing equipment, or to finance our growth. Navesink Device Initiatives, Sovereign Partners and Licgo Partners ended their investments with the company in September 2016 and December 2017 respectively. Alpha financed us repeatedly in 1Q, 2Q and 4Q 2016 and 2Q, 3Q and 4Q 2017, 2Q and 3Q 2018, and 1Q and 2Q 2019 and finally in 2Q and 3Q 2020. In 2020, to help us fund our Covid-19 product endeavors, Alpha loaned us an additional \$2.35 million to carry on and complete our GenViro! Swift development and testing. Alpha also financed our acquisition of new specialty manufacturing equipment to facilitate our contract manufacturer in Korea as they develop and manufacture our GenChoice! product.

Additional Background and Foundation

On April 30, 2014 we first implemented our FDA mandated Quality Plan and are now operating as the manufacturer (operator) of the GenUltimate! test strip. We have implemented subsequent Quality Plans with our Korean contract manufacturer for our GenUltimate! product. Similar Quality Plans and/or FDA registrations are in place for the company’s GenChoice! and GenUltimate! TBG products, and for our GenAccord and GenCambre products later in the coming months. Our overall Quality Plan, a living document, is in its fifth re-write.

The company brought suit against Shasta and the former contract manufacturer in Pennsylvania in November 2018. On December 31, 2018 the Pennsylvania court awarded the company with a \$3.6 million judgment against Shasta. We were pursuing collection of this judgment in Minnesota, California, Oregon and Pennsylvania. To that end we filed for a Writ of Attachment against Shasta for the \$3,600,000. This Writ will allow the company to bring an end to the litigation against Shasta in California and Minnesota (in an action stat that includes our FDA lawyer). On June 29, 2019 Settlement documents were executed by Shasta and the company to bring an end to the litigation in the four states. Shasta agreed to drop all claims against the company, and we agreed not to further pursue Shasta (but not Conductive Technologies, Inc. and not the former DECN shareholders). After five years, the company can now value its acquisition of the GenStrip technology and Marks, and any knowhow. We have done so as of the period ended September 30, 2019 (see financials) and have realized a gain in the period.

We continue to litigate in Pennsylvania against the former contract manufacturer, who apparently while working for us, was also working against us and with Johnson & Johnson. The company is also pursuing stockholders who may have traded stock based on information and documents provided by Shasta, or who were given confidential documents by Shasta, gained through the litigation discovery and provided to these shareholders, who then posted the information on public message boards.

We currently employ six professionals at or managed remotely through our business office located at 2660 Townsgate Road, Suite 300, Westlake Village, California 91361. In addition, we maintain three part-time positions located throughout the United States. We also maintain a Quality Assurance office through our exclusive agent in Seoul, Korea as a means to fulfill our quality commitments to the FDA. Our telephone number is (805) 446-1973 and our website addresses are and www.pharmatechsolutionsinc.com and www.genultimate.com, and www.decisiondiagnostics.com. Additional web sites will be added for our GenChoice! product, our GenUltimate! TBG product and our GenViro! Covid-19 testing products.

As a part of the company’s strategic plans, we have applied (to register) for fourteen Trademarks with the USPTO. The company’s Genstrip product is a registered Trademark of Shasta Technologies LLC. Now that we own this Mark, we do not intend to renew it. Our applications were filed with the USPTO in 1Q and 2Q 2015 and throughout 2016, 2017, 2018, 2019, 2020 and 2021. The company intends to use these Marks, as granted, to brand new products, rebranding of existing products, and the establishment of a family of Marks associated with our company and its place in our industry.

As of June 30, 2021, the company has received registration confirmation from the USPTO for the following Marks:

“Alltara!” “GenUltimate!” “GenSure!” “GenChoice!” “GenAccord!” “GenCambre!”
“GenUltimate! TBG” “Firefly!” “ConsumerValue!” “Infatig” “Medicius!”

Our marks for Alltara!, ConsumerValue!, Infatig!, and Medicius! will be used for product families as an integral part of our relationships with the “big-box” entities. We have several Marks that were filed to further enhance our GenUltimate! TBG product and technology. These Marks were first filed in 2Q 2019. All of these Marks were granted by the USPTO in 1Q 2021.

The company’s stock currently trades on the OTCMarkets OTC Expert Market tier. The company is and has been a current filer with OTCMarkets. The company’s shares are DTC and DWAC eligible. On April 22, 2020 the company’s shares were suspended from trading by the U.S. Securities and Exchange Commission (“SEC”). This suspension expired on May 8, 2020. On May 8, 2020 with the lifting of the SEC imposed suspension, our shares began trading again on the OTC Expert market. Subsequently the company appealed the original suspension asserting it had been implemented as a result of inaccurate information. Some 16 months have passed since the appeal was filed, and 13 months since the last submission. Certain brokers/marketmakers were supposedly in the process of filing a Form 15c2-11 to revive the company’s trading on the OTC Pink market, where we traded prior to April 22, 2020.

In mid-2018 the company chose to file a Regulation A offering in an effort to improve its disclosure to the SEC. The company had planned to use this filing, reviewed by the SEC without comment on August 23, 2018, to move toward uplist on the OTCMarkets exchange in 2019. In February 2019 the company, after completing all of the ancillary tasks required of a Reg. A filer, amended its registration with the SEC, a necessary requirement. Subsequently, the company’s stock price improved so that the registration offering price was much lower than the stock trading price. In early March, during the stock price rise, the company was informed that a certain party, who at that point claimed to own approximately 4% of the company’s outstanding shares, wished to buy the entire Reg. A offering on the date said offering became qualified. That would allow this certain party to gain control of the company for approximately \$5.3 million, a value much lower than the trading price of the company’s common stock. This was/is a common predatory M&A strategy often used by private equity funds. On March 18, 2019, acting on a resolution by the company’s Board of Directors, the Reg. A registration was withdrawn.

In February 2019 the company was approved for Deposit/Withdrawal at Custodian (DWAC) a method of electronically transferring new shares or paper [share certificates](#) to and from the [Depository Trust Company \(DTC\)](#) using a Fast Automated Securities Transfer (FAST) service transfer agent as the distribution point. DWAC transfer is a method employed by most funds and large investors.

In December, 2020 the company and its CEO Keith Berman were sued in Federal District Court in New York by the U.S. Securities and Exchange Commission (SEC). The SEC action sought injunctive and other relief based on allegedly false and misleading information contained in a series of press releases issued by the company concerning the development and potential sales of the company’s GenViroCovid test kits. This lawsuit was almost immediately stayed by the Federal court and no subsequent activity has taken place.

Simultaneously with the filing of the SEC action the U.S. Department of Justice unsealed the indictment of the company’s CEO based on essentially the same allegations as are contained in the SEC lawsuit. A superseding indictment was unsealed in May, 2021. The company was not indicted by the DOJ. Subject to COVID protocols and adequate protection of all participants, the DOJ action is currently scheduled to be tried in Washington, D.C. Federal District Court commencing on January 4, 2022.

Recent Business Milestones:

In FY 2030 and FY 2021 the company has accomplished the following milestones.

1. In 2020 we completed design of two Covid-19 test kits for commercial sale, using saliva as a testing medium (see Business Section Introduction).
2. The company, through its EU based distributor achieved registration of its GenViro Swift products and meter through the German BfArM agency of the German Federal government, described as the German equivalent of the U.S. FDA.
3. We have prepared for introduction a premier version of our popular GenUltimate! test strip for launch. This type of product differentiation is common for mature product lines.

4. We completed the design and manufacture of PetSure! glucose test strips for the international markets, and completed development of our GenChoice!, GenUltimate!, 4Pets and GenUltimate! TBG products.
5. The company initiated a marketing program to the on-line Marketplaces sponsored by pharmacy chain, department store and grocery store retailers, as well as mass merchandisers, and including the largest retailers. This program has so far been the most successful endeavor since our inception.
6. The company has retained patent counsel to file patents for our GenUltimate! TBG and Precise meters and test strips, and for our newest adaptation, our two GenViro! Covid-19 test kits. Provisional patents have been filed with the USPTO.

Financing Requirements/Financing Arrangements

We anticipate that we will require up to \$250 million in [trade debt financing](#) to finance our anticipated sales of our GenViro!, (especially GenViro! Swift kits) GenUltimate!, GenUltimate! Premier, GenUltimate! TBG, and GenChoice!. We anticipate receipt of a revolving line of credit from a European lender or fund.

Trade debt financing is traditional debt where the borrower executes short term Notes with a lender, usually from a revolving line of credit used to finance pre-payment for inventory. The company anticipates drawing down the trade debt in installments of first \$1 million, then \$2 million, and finally \$5 million at a time. Money for this type of debt is typically available from wealthy individuals, factoring organizations, finance companies or other financial institutions -- although at higher rates than bank lending. Fortunately the current private lending environment offers opportunities. With the approval of our GenViro! Swift products by the German agency BfArM in early May 2021, we have begun our efforts to secure this commercial financing. One overseas financier has already offered to loan up to \$5.4 million with a follow-on loan of another \$8.0 million. Further details will be available about these proposed transactions in the Quarterly Report for 3Q 2021.

The company has in the past noted substantial disinformation in public forums regarding trade debt financing. We reiterate that our plan calls for us to borrow money, finance manufacturing of our product purchases, and then pay the money back to the lender through sales of our products along with interest on the loans. **Complicated derivative and/or toxic equity financing is NOT expected to be used for trade transactions.** However, without substantial financing at acceptable terms our sales will be curtailed.

Beginning in March 2020 the company entered into eight Notes (loans) with its then main investor, Alpha Capital Anstalt, for a total of \$2.35 million (plus \$210,000 from a 2019 partially paid down Note). All of the loans from Alpha were term loans and did not include any conversion features. All eight of these Notes are overdue and technically in default. However, we intend to negotiate a work-through with the lender, a long time investor in the company.

In 1Q 2021 the company entered into a short series of agreements with an investor. These agreements include a Note for \$250,000, bonus Preferred stock and a royalty agreement based on GenViro! sales, where the royalties will be used to retire the Note. In addition, this investor is also planning to be a distributor of the company's GenViro! products, currently in Central America (and potentially) Mexico. Compensation for the distribution agreement will accrue to this investor from the distribution agreement itself. The balance sheet and financial statements for the periods ending March 31, 2021 and June 30, 2021 include this investment. Later periods will reflect these agreements.

In 1Q 2021 CEO Keith Berman guaranteed additional loans for approximately \$180,000 from two lenders. These two loans replaced a similar loans entered into in November 2019 for \$250,000.00 that was also guaranteed by Mr. Berman. These November 2019 loans were fully paid at term. The balance sheet and financial statements for the period ending December 31, 2020 include this investment on a pro-rata basis since the loans were taken down at the end of 1Q 2021. Later periods will reflect these agreements.

In early 2020 Mr. Berman guaranteed a \$100,000 bank loan which has been partially amortized and drawn down again three times.

Mr. Berman has also agreed to guarantee additional trade debt loans that were provided to the company. Some \$105,000 in trade debt loans have been made available to the company by Mr. Berman primarily through use of his American Express account.

In 2Q 2021 the company's CEO Keith Berman entered into a Note Agreement with the company where he loaned the company an additional \$325,000. These loans come from a recent family inheritance. This particular loan as well as previous loans and personal guarantees provided by Mr. Berman to the company now total in excess of \$900,000. The listing of Mr. Berman's loans and guarantees appear earlier in this document, although current OTC Market rules only require that this document list loan activity for the last two years, the company currently provides a complete listing dating to January 2018.

Mr. Berman has made loans to the company dating back to 2006 totaling where his first loans totaled \$130,000. Despite inaccuracies that appear regularly in public forums, stating to the contrary, all transactions involving Mr. Berman are accounted for (and always have been), and are fully reflected in the company's GAAP financial statements prepared by its CPA.

In March 2011 we executed an agreement with Alpha Credit Resources ("ACR") for a third time (Agreement #4) in order to obtain additional debt financing. After the expiration of that agreement, in November 2013 we executed a new line of credit with Alpha Credit Resources, replacing our previous line with the same and an earlier entity composed of the same principals. This credit line was for \$12.5 million. We paid the various fees, paid for the documentation, and provided unrestricted securities as compensating balances. We, unfortunately, were never able to draw down any credit financing from ACR. Each time we attempted to draw on the credit line we were advised that ACR had not yet hired a manager for our account, nor had they opened a "control" bank account to handle the transactions. On December 14, 2015 this credit line expired without a single completed transaction. Subsequently we learned that ACR and its parent, Platinum Credit became the subject of several Federal criminal investigations and trials. In September 2016, the major funds controlled by Platinum, and apparently included the smaller ACR fund, filed for liquidation. Once notified of this liquidation the company has attempted to seek return of the fees and securities paid to ACR in 2011, 2013 and 2014. The company believes that certain of the former principals of ACR (Platinum) committed repeated frauds against the company and its shareholders. Amongst these frauds were shares ACR (Platinum) granted to themselves from a jointly administered escrow account which were then pre-sold. In March 2021 the Trustee for the liquidation of the funds brought suit against the company in an attempt to compel the company into converting Preferred shares into millions of common stock shares the Trustee claims ACR (Platinum) owns. The company believes it has meritorious defenses to the Trustee's claims.

We will from time to time continue to seek a combination of equity and long-term debt financing as well as other traditional cash flow and asset backed financing to meet our financing needs and to reduce our overall cost of capital. Additionally, in order to accelerate our growth rate and to finance general corporate activities, we may supplement our existing sources of funds with financing arrangements at the operating system level or through additional short-term borrowings. As a further capital resource, we may sell or lease certain rights or assets from our portfolio as appropriate opportunities become available. However, there can be no assurance that we will be able to obtain any additional financing, on acceptable terms or at all.

Contingencies and Litigation

We transact commerce in several medical products market channels. We also transact commerce by licensing our proprietary medical software that functions by moving confidential medical data through our proprietary medical information technology devices and networks. Our original Genstrip product required initial regulatory approval by the USFDA as well as on-going USFDA approvals during the product life cycle. Further, Genstrip/GenUltimate required medical patient trials and competes directly with a major platform manufacturer. We insure against any claims made against the company for our Genstrip/GenUltimate product.

Our GenSure and GenUltimate TBG products are sold only in international markets. We are protected against claims of patent and/or trademark infringement by virtue of our 2016 settlement agreement with Johnson & Johnson and two of its divisions.

Our GenChoice! products will be sold worldwide. The company will have to protect against claims of infringement for this product. Patent and trademark infringement suits are often filed for strategic business reasons, having only a passing relationship to the patents or trademarks claimed to be at issue.

Healthcare, especially those segments where the company competes, is also very litigious. Competing companies often use litigation as a marketing tool, bringing litigation as a means to protect market share and limit market exposure. The medical industry is also intertwined. From time to time, we may become involved in claims and litigation that arise out of the normal course of business, such as litigation that emerges from disputes over damaged, missing or contaminated product, litigation that arises over payment disputes or claims of fair value. We may also become involved in disputes that arise over the business or business practices of our suppliers,

payers and customers. It is not uncommon in our industry to find that a litigant has filed claims in multiple jurisdictions involving the same transaction or a single transaction. The company maintains substantial insurance coverage against suits that may arise over issues of damaged, recalled or counterfeit product and other product liability issues. The company has also been a victim of the unapproved acts of prior management. These acts have resulted in claims from individuals and entities since the Board relieved former management of duty in 2006. Nonetheless, these claims have resulted in the use of management time and company resources to investigate, litigate, or settle. In addition, the company accrues contingent legal fees and product liability fees. As of September 30, 2020, our accrual was \$485,069.

From time to time, the company may also be subject to demands from individuals or entities. These demands and disputes may consume management time and company resources. Other than as noted below, if there is such a disclosure, there are no pending matters at the current time that in management's judgment may be considered potentially material to us.

In December 2018 the company and Mr. Berman were sued by a former employee who made employment practices claims. This employee had been terminated some 16 months earlier, for insubordination. The company filed a counter-suit against the former employee for misappropriating and hiding company property, secrets, and for violating HIPAA statutes as a result of these actions. The company and Mr. Berman were both insured against these types of lawsuits. In 1Q 2020, with the assistance and resources of its insurer, this lawsuit was settled.

We were in litigation with Lifescan Inc. a subsidiary of Johnson & Johnson beginning in September 2011. Lifescan had maintained throughout that our Genstrip (now known as GenUltimate!) product infringed on three of their patents. One of these patents became the subject of peripheral litigation activities, and two Appeals (one for each side) to the U.S. Appeals Court for the Federal Circuit (the patents appeals court). In January 2016 the Court of Appeals for the Federal Circuit ruled in its Mandate that this one foundational patent and the claims made by the assignee Lifescan, Inc. was struck (killed) due to obviousness (a clever wording meant to obscure a connection between the Lifescan, Inc. invention and earlier generation technologies dating back to the late 1970s). Throughout this Appeal process, and a litigation process waged through the USPTO, the company prevailed. In addition, as a result of certain claims and allegations made by Lifescan after the close of the USPTO final determination (in favor of the company), the office of the Solicitor General intervened against Lifescan Inc. in the Federal Circuit court and was of great assistance in getting the Lifescan, Inc. patent revoked. Nonetheless the seeming baseless allegations and claims made by Lifescan against the company have taken their toll, limited our ability to sell our GenStrip (now known as GenUltimate) to large entities ("big box stores") and greatly extended the court processes.

In May 2016 the company became aware of a clause Lifescan had inserted in its Franchise agreements. This clause set a penalty structure whereby should any Franchisee who also bought non-Lifescan products (but more clearly our GenUltimate) they would lose their access to product rebates, and in certain instances their Franchise. Once aware of these illegal tie-ins the company complained to the Federal government, and in January 2017, for the first time since the onset of litigation with J&J, the tie-in clause was globally lifted by J&J. During the pendency of the 2011 and 2012 lawsuits, Lifescan was guilty of a number of unethical practices.

In March 2016 the company filed suit against Johnson & Johnson and two Lifescan divisions through our two IP subsidiaries. DECN filed the lawsuit in the United States District Court, District of Nevada, in Las Vegas, NV, naming Johnson & Johnson and its divisions Lifescan, Inc. and Lifescan Scotland Ltd. for alleged infringement in relation to U.S. Patent numbers 6,153,069, an apparatus patent, and 6,413,411, a method patent. The suit sought at least \$400 million in provable damages. The company lost this lawsuit on a contested technicality, and also lost its appeal.

In November 2018 the company filed a lawsuit in Pennsylvania court against Conductive Technologies, Inc. (CTI) and Shasta Technologies LLC, alleging, among other things, that these two former partners colluded along with Lifescan, Inc. to illegally embargo the company's GenUltimate! product and technology, and to attempt to seize this product and associated Intellectual Property. The suit emerged as a result of a settlement the former partners entered into with Lifescan, Inc. and Johnson & Johnson to settle their issues (at our expense) in the above discussed patent infringement lawsuits of 2011 and 2012. On December 31, 2018 the Pennsylvania court granted the company a judgment in the amount of \$3,600,000 against Shasta Technologies LLC. The company had been in the process of enforcing the judgment in the states of Minnesota, Oregon (Shasta's domicile), and California. In late April 2019 the company filed and received a Writ of Attachment from the State of California Superior Court and proceeded to execute on this Writ.

Activities to enforce the judgment against Shasta in Minnesota and California ended the litigation and collection activities against Shasta as of the period ended June 30, 2019. The company, upon conclusion of the litigation then valued its acquisition of technology and Marks in the financials for the period ended June 30, 2019. The company shows a one-time gain in the 2Q 2019 period. Litigation against CTI continued until a recent settlement in 3Q 2021.

In May 2020, just prior to the end of the 10-day trading suspension imposed by the SEC, the company petitioned the SEC to terminate the stock trading suspension. It has been more than 15-months since the suspension which the SEC unilaterally imposed and the Company is still waiting for a decision on its petition.

In December, 2020 the company and its CEO Keith Berman were sued in Federal District Court in New York by the U.S. Securities and Exchange Commission (SEC). The SEC action sought injunctive and other relief based on allegedly false and misleading information contained in a series of press releases issued by the company concerning the development and potential sales of the company's GenViroCovid test kits. This lawsuit was almost immediately stayed by the Federal court and no subsequent activity has taken place.

Simultaneously with the filing of the SEC action the U.S. Department of Justice unsealed the indictment of the company's CEO based on essentially the same allegations as are contained in the SEC lawsuit. The company was not indicted by the DOJ. A superseding indictment was unsealed on May 11, 2021. Subject to COVID protocols and adequate protection of all participants, the DOJ action is currently scheduled to be tried in Washington, D.C. Federal District Court commencing on September 20, 2021. There has been a lot of activity in this case, including upcoming activity that should commence as this report is filed.

In March 2011 we executed an agreement with Alpha Credit Resources ("ACR") for a third time (Agreement #4) in order to obtain additional debt financing. After the expiration of that agreement, in November 2013 we executed a new line of credit with Alpha Credit Resources, replacing our previous line with the same and an earlier entity composed of the same principals. This credit line was for \$12.5 million. We paid the various fees, paid for the documentation, and provided unrestricted securities as compensating balances. We, unfortunately, were never able to draw down any credit financing from ACR. Each time we attempted to draw on the credit line we were advised that ACR had not yet hired a manager for our account, nor had they opened a "control" bank account to handle the transactions. On December 14, 2015 this credit line expired without a single completed transaction. Subsequently we learned that ACR and its parent, Platinum Credit became the subject of several Federal criminal investigations and trials. In September 2016, the major funds controlled by Platinum, and apparently included the smaller ACR fund, filed for liquidation. Once notified of this liquidation the company has attempted to seek return of the fees and securities paid to ACR in 2011, 2013 and 2014. The company believes that the former principals of ACR (Platinum) committed repeated frauds against the company and its shareholders. Amongst these frauds were shares ACR (Platinum) granted to themselves from a jointly administered escrow account which were then pre-sold. In March 2020 the Trustee for the liquidation of the funds brought suit against the company in an attempt to compel the company into converting Preferred shares into millions of common stock shares the Trustee claims ACR (Platinum) owns. The company has meritorious defenses and some 5 years after the demise of Platinum, has not been shown by the Trustee, or ACR or Platinum that they have possession of any of the stock, giving rise to the claims. Both parties are seeking settlement of this suit and have discussed settlement terms on several occasions with the Trustee of the Platinum estate.

In March 2021 the company and its CEO were served with a purported class action lawsuit as a result of the SEC and DOJ actions, filed in the U.S. District Court for the Central District of California. The company carries no Directors and Officers' liability (and claims defense) insurance. Upon learning of the company's lack of insurance, Plaintiff's lawyers extended to the defendants' what amounts to indefinite time to answer the complaint and no subsequent activity has taken place.

In April 2021 the company, its subsidiary Pharma Tech Solutions, Inc. and its CEO were served with an Amended complaint, the original complaint never having been served, by certain investors, who made the last of their investments in 2017. This suit follows a pattern of demands made against the company and its CEO made by this group(s) dating to 2014. The company and Mr. Berman are contesting this suit vigorously.

- A. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

The company has five wholly owned subsidiaries, Decision IT Corp., PharmaTech Solutions, Inc. PharmaTech Direct Corp., PDA Services Inc., Pharmatech Sensor Development Corp. All of the subsidiary corporations reside in the same building that hosts Decision Diagnostics Corp. We report on a consolidated basis. In July 2021 the company's PDA Services, Inc. subsidiary was closed down, having completed all of its work.

- B. Describe the issuers' principal products or services, and their markets

Decision Diagnostics Corp. is a worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of

glucose, the PetSure! glucose test strip for the glucose testing of dogs and cats, a test strip designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter, and the GenUltimate! 4Pets Glucose system a proprietary glucose measuring system inclusive of the company's GenUltimate! 4Pets test strip and Advantage meter, for the testing of dogs, cats and horses. The company also has its GenSure! glucose test strip, a product for off-shore sales which is complete and available for sales, but will primarily be sold as an international private label market entry. GenSure! and the legacy glucometers that accept this test strip no longer meet most International (ISO) standards. In September 2020 the company introduced its GenViro! Covid-19 detection kits. Immediately upon this introduction the company began to receive inquiries from interested parties. Subsequently we have executed agreements with a number of parties for the distribution of our GenViro! Covid-19 Swift kits, our glucose test strips, or both product lines. We currently cover approximately 50 International sovereigns.

- C. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

The company has five wholly owned subsidiaries, Decision IT Corp., PharmaTech Solutions, Inc. PharmaTech Direct Corp., PDA Services Inc., Pharmatech Sensor Development Corp. All of the subsidiary corporations reside in the same building that hosts Decision Diagnostics Corp. We report on a consolidated basis. In July 2021 the company's PDA Services, Inc. subsidiary was closed down, having completed all of its work.

- D. Describe the issuers' principal products or services, and their markets

Decision Diagnostics Corp. is a worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose, the PetSure! glucose test strip for the glucose testing of dogs and cats, a test strip designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter, and the GenUltimate! 4Pets Glucose system a proprietary glucose measuring system inclusive of the company's GenUltimate! 4Pets test strip and Advantage meter, for the testing of dogs, cats and horses. The company also has its GenSure! glucose test strip, a product for off-shore sales which is complete and available for sales, but will primarily be sold as an international private label market entry. GenSure! and the legacy glucometers that accept this test strip no longer meet most International (ISO) standards. In September 2020 the company introduced its GenViro! Covid-19 detection kits. Immediately upon this introduction the company began to receive inquiries from interested parties. Subsequently we have executed agreements with a number of parties for the distribution of our GenViro! Covid-19 Swift kits, our glucose test strips, or both product lines. We currently cover approximately 50 International sovereigns.

- E. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

The company has five wholly owned subsidiaries, Decision IT Corp., PharmaTech Solutions, Inc. PharmaTech Direct Corp., PDA Services Inc., Pharmatech Sensor Development Corp. All of the subsidiary corporations reside in the same building that hosts Decision Diagnostics Corp. We report on a consolidated basis.

- F. Describe the issuers' principal products or services, and their markets

Decision Diagnostics Corp. is a worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose, the PetSure! glucose test strip for the glucose testing of dogs and cats, a test strip designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter, and the GenUltimate! 4Pets Glucose system a proprietary glucose measuring system inclusive of the company's GenUltimate! 4Pets test strip and Advantage meter, for the testing of dogs, cats and horses. The company also has its GenSure! glucose test strip, a product for off-shore sales which is complete and available for sales, but will primarily be sold as an international private label market entry. GenSure! and the legacy glucometers that accept this test strip no longer meet most International (ISO) standards. In September 2020 the company introduced its GenViro! Covid-19 detection kits. Immediately upon this introduction the company began to receive inquiries from interested parties. Subsequently we have executed agreements with a number of parties for the distribution of our GenViro! Covid-19 Swift kits, our glucose test strips, or both product lines. We currently cover approximately 50 International sovereigns.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is \$3500.00 per month on a month-to-month basis. We also maintain a Quality Assurance office in at the facility of our exclusive manufacturer's representative in Seoul, Korea. We also receive space in a specialty public warehouse in Miami, FL, which serves as our importing, exporting and shipping and receiving terminal. We also contract with a customs broker in Miami who represent the company in all official import and export activities.

7) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information regarding any person or entity owning 5% or more of the issuer, as well as any officer, and any director of the company, regardless of the number of shares they own.

If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.

See below

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Keith M. Berman	CEO & CFO	Westlake Village, CA	480,103	Common	<1%	Mr. Berman is the sole officer and director.

Our executive officers, directors, and key employees are:

Name	Age
Keith Berman CEO, CFO, Director	67

Our shareholders elect our directors and our Board of Directors appoints our officers. As of the date of this filing, we have not held an annual meeting. All current director(s) have been held over until such time the annual meeting is held. Vacancies on our board are filled by the board itself. Set forth below are brief descriptions of the recent employment and business experience of our executive officers and directors.

During 1Q 2020, Robert Jagunich left the Board of Directors in January 2020 effective February 1, 2020.

Keith Berman has served as Chief Financial Officer, Secretary, Treasurer and Director of the Company since January of 2003. He was elected CEO in July 2017. Mr. Berman has been involved in the development of in-vitro diagnostic products, dry chemistry products, and healthcare software including Intranet and Internet systems for the past 43 years. From July 1999 to present, Mr. Berman has held the position of President, founder and director of Caredecision.net, Inc. a private company engaged in e-health technology development. From March 2001 through June 2002 Mr. Berman also held the Position of President and Director of Medicius, Inc. From January 1996 to June 1999 Mr. Berman was the President and founder of Cymedix, the operating division of Medix Resources, Inc., later Ramp Corp. (RCO). Cymedix was a pioneer company in what was then known as i-health (Internet healthcare) now the e-health industry. Mr. Berman's professional background provides the Company with business management experience and an in depth knowledge of our industry. Mr. Berman received a BA in 1975 and an MBA in 1977, from Indiana University.

Mr. Berman, officer and director, works 80 hours each week for the company and its subsidiaries. Mr. Berman also did part-time work for two predecessor (to its subsidiary Pharma Tech Solutions) companies.

The following table sets forth information the remuneration of our Principal Executive officer for the years ended December 31, 2019, 2020 and 1Q and 2Q 2021:

Summary Compensation Table

Name and Principal Position	Year	Salary (\$)	Bonus (\$)	Stock Awards (\$)	Option Awards (\$)	Non- Equity Incentive Plan Compensation (\$)	Nonqualified Deferred Compensation Earnings (\$)	All Other Compensation (\$)	Total (\$)
Keith Berman, CFO and PEO	2019	\$ -0-	-0-	\$ -0-	-0-	-0-	-0-	-0-	\$ -0-
	2020	\$ -0-	-0-	\$ -0-	-0-	-0-	-0-	-0-	\$ -0-
	2021	\$6245.00	-0-	\$ -0-	-0-	-0-	-0-	-0-	\$ -0-

Mr. Berman has served as Chief Financial Officer since January 2003 and as Principal Executive Officer since August 2006. During the fiscal years ended December 31, 2019 and 2020 Mr. Berman received no salary or employment fee compensation from the company. In March 2021, the Board of Directors approved cash compensation for Mr. Berman not to exceed \$8000.00 per month.

The table above reflects 1Q and 2Q 2021 compensation that Mr. Berman received. For 1Q 2021 Mr. Berman received \$2,300.00 in fee compensation (salary) and in 2Q 2021 \$3,945.00.

Throughout the product development phase of the company, Mr. Berman chose for many years not receive any form of cash compensation from the company as a result of our limited cash flow. Mr. Berman agreed to accept stock option awards from time to time, his last award in December 2019, as his compensation until such time as the Company had the necessary resources available to provide a traditional compensation plan.

In March 2021, the Board of Directors approved cash compensation for Mr. Berman not to exceed \$8000.00 per month.

8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

There have been no criminal convictions. However, the U.S. Department of Justice unsealed the indictment of the company's CEO for one count of securities fraud, and one count of providing false information to a governmental entity (the U.S. SEC). The company was not indicted by the DOJ. On or about May 12, 2021 the Grand Jury allowed a superseding indictment which contained additional counts of wire fraud and obstruction of proceedings. Subject to COVID protocols and adequate protection of all participants, the DOJ action is currently scheduled to be tried in Washington, D.C. Federal District Court commencing on January 4, 2022. Mr. Berman, the CEO is defending the indictment vigorously and remains at his position with the company.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

- . The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

See Litigation and Contingencies section in this document.

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Firm: Law Offices of Thomas C. Cook
Address 1: 10470 W, Cheyenne Ave.
Address 2: Suite 115, PMB 303
Address 3: Las Vegas, NV 89129
Phone: (702) 524-9151
Email: tccesq@aol.com

Firm: see above
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Accountant or Auditor

Name: none
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s), including, counsel, advisor(s) or consultant(s) **that assisted, advised, prepared or provided information with respect to this disclosure statement**, or provided assistance or services to the issuer during the reporting period.

Name: None

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Keith M. Berman certify that:

1. I have reviewed this Quarterly Report for the period ended June 30, 2021, of Decision Diagnostics Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 19, 2021

Chief Executive Officer

/s/ Keith M. Berman

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

Principal Financial Officer:

I, Keith M. Berman, CFO certify that:

1. I have reviewed this Quarterly Report for the periods ended June 30, 2021 and December 31, 2020 of Decision Diagnostics Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 19, 2021

Chief Financial Officer

/s/ Keith M. Berman

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)



Decision Diagnostics Corp.

OTC Pink Balance Sheet, Statements of Equity & Cash Flows, Footnotes to Balance Sheet

Quarterly Report for Period Ended

June 30, 2021

The following pages present the unaudited financial statements along with Statements of Equity and Cash Flows, and the Footnotes to the Balance Sheet for Decision Diagnostics Corp., for the quarters ended June 30, 2021, and 2020. The financial statements have been prepared in accordance with generally accepted accounting principles.

Trading Symbol: DECN

CUSIP Number: 243443 108

Decision Diagnostics Corp.
Consensed Consolidated Balance Sheets
(Unaudited)

	June 30, 2021	June 30, 2020
Assets		
Current assets:		
Cash	\$ 216,004	\$ 650,077
Accounts receivable, net	899,548	945,205
Inventory	149,410	171,130
Prepaid expense	-	499
Total current assets	<u>1,264,962</u>	<u>1,766,911</u>
Fixed assets:		
Specialty manufacturing equipment	837,565	802,315
	<u>837,565</u>	<u>802,315</u>
Less accumulated depreciation	-	-
Fixed assets, net	<u>837,565</u>	<u>802,315</u>
Other assets:		
Intellectual property	738,830	743,865
Patent licenses, net value	2,490,825	2,490,825
Total other assets	<u>3,229,655</u>	<u>3,234,690</u>
Total assets	<u>\$ 5,332,182</u>	<u>\$ 5,803,916</u>
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 1,556,563	\$ 1,646,899
Accrued interest	-	-
Contingent legal fees	240,000	240,000
Short term inventory financing	108,000	310,379
Notes payable and short term debt with warrents (Note 5)	<u>3,142,346</u>	<u>2,893,346</u>
Total current liabilities	<u>5,046,909</u>	<u>5,090,624</u>
Contingencies	245,069	245,069
Stockholder equity (deficit):		
Preferred stock, \$0.001 par value, 3,738,500 shares authorized, no shares issued and outstanding as of June 30, 2021 and June 30, 2020	-	-
Preferred "B" stock, \$0.001 par value, 2,500 shares authorized, 1,665 and 1,864 shares issued and outstanding as of June 30, 2021 and June 30, 2020	2	2
Preferred "C" stock, \$0.001 par value, 10,000 shares authorized, 6,925 and 6,663 shares issued and outstanding as of June 30, 2021 and June 30, 2020	7	6
Preferred "D" stock, \$0.001 par value, 500 shares authorized, 190 and 180 shares issued and outstanding as of June 30, 2021 and June 30, 2020	-	-
Preferred "E" stock, \$0.001 par value, 1,250,000 shares authorized, 747,540 and 747,540 shares issued and outstanding as of June 30, 2021 and June 30, 2020	748	747
Common stock, \$0.001 par value, 494,995,000 shares authorized, 357,150,583 and 300,623,608 shares issued and outstanding as of June 30, 2021 and June 30, 2020	357,151	300,414
Common stock unissued, 137,844,417 and 1,410,000 shares as of June 30, 2021 and June 30, 2020		1,411
Subscription receivable	(82,250)	(82,250)
Unit offering finders' fees	(321,344)	(321,344)
Additional paid in capital	79,952,965	68,282,654
Retained (deficit)	<u>(79,867,074)</u>	<u>(67,713,417)</u>
Total stockholders' equity	<u>40,204</u>	<u>468,223</u>
Total liabilities and stockholders' equity	<u>\$ 5,332,182</u>	<u>\$ 5,803,916</u>

The accompanying Notes are an integral part of these financial statements

Decision Diagnostic Corp.
Condensed Consolidated Statements of Operations
(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2021	2020	2021	2020
Revenue	\$ 552,385	\$ 362,864	\$ 1,090,184	\$ 936,656
Cost of Sales	417,673	262,754	847,389	638,337
Gross profit	134,712	100,110	242,795	298,319
Expenses:				
General & administrative	187,601	178,765	480,293	789,274
Consulting	26,900	18,300	37,827	34,049
Compensation expense	50,303	75,343	102,892	166,031
Professional fees	107,277	234,704	313,168	323,142
Total expenses	<u>372,081</u>	<u>507,112</u>	<u>934,180</u>	<u>1,312,496</u>
Net operating (loss)	(237,369)	(407,002)	(691,385)	(1,014,177)
Other income (expense)				
Financing costs	(7,200)	(16,405,565)	(14,400)	(16,434,065)
Interest expense, net	(57,000)	(107,102)	(114,000)	(339,889)
Loss on write-down of obsolete inventory	-	(304,276)	-	(304,276)
Other income - PPP grant	-	10,000	-	10,000
Gain on inventory liabilities	-	-	-	100,000
Total other income (expense)	<u>(64,200)</u>	<u>(16,806,943)</u>	<u>(819,785)</u>	<u>(16,968,230)</u>
Taxes:				
State	-	(1,086)	-	(1,086)
Net Income (loss)	\$ <u>(301,569)</u>	\$ <u>(17,215,031)</u>	\$ <u>(1,511,170)</u>	\$ <u>(17,983,493)</u>
Add: Dividends declared on preferred stock	-	-	-	-
Income available to common shareholders'	\$ <u>(301,569)</u>	\$ <u>(17,215,031)</u>	\$ <u>(1,511,170)</u>	\$ <u>(17,983,493)</u>
Weighted average number of common shares outstanding - basic and fully diluted	<u>356,430,583</u>	<u>271,385,939</u>	<u>356,430,583</u>	<u>271,385,939</u>
Net loss per share - basic and fully diluted	\$ <u>(0.00)</u>	\$ <u>(0.06)</u>	\$ <u>(0.00)</u>	\$ <u>(0.07)</u>

The accompany Notes are an integral part of these financial statements

Decision Diagnostics Corp
Statements of Shareholders Equity
(Unaudited)

Date	Shareholder	Preffered "B"		Preferred "C"		Preferred "D"		Preferred "E"		Common Stock			Authorizer Unissuet	Subscription Receivable	Finders Fees	Retainec (Deficit)	Total
		# Shares	Amt	# Shares	Amt	# Shares	Amt	# Shares	Amt	# Shares	Amt	APIC					
BALANCE DECEMBER 31, 2020		1,665	2	6,870	7	180	-	747,540	748	354,495,583	354,496	79,929,070	1,411	(82,250)	(321,344)	(78,593,273)	483,532
1/12/2021 THOMAS NELSON - NEW ISSUANCE										360,000	360	3,240					3,600
1/12/2021 KEN STOCK TRUST - NEW ISSUANCE										180,000	180	1,620					1,800
1/12/2021 JAN STOCK TRUST - NEW ISSUANCE										180,000	180	1,620					1,800
1/12/2021 LICGA PARTNERS - NEW ISSUANCE					210	0											-
1/12/2021 SOVERIGN PARTNERS LLC - NEW ISSUANCE					70	0											-
1/12/2021 PARADIGM CAPITAL - NEW ISSUANCE							10	0									-
1/21/2021 NAVESINK DEVICE INITIATIVES - CONVERSION										1,215,000	1,215	10,935					12,150
1/26/2021 NAVESINK DEVICE INITIATIVES - CONVERSION					(225)	(0)											-
NET LOSS																(972,232)	
BALANCE, MARCH 31, 2021		1,665	2	6,925	7	190	0	747,540	748	356,430,583	356,431	79,946,485	1,411	(82,250)	(321,344)	(79,565,505)	502,882
4/13/2021 THOMAS NELSON - NEW ISSUANCE										360,000	360	3,240					3,600
4/13/2021 KEN STOCK TRUST - NEW ISSUANCE										180,000	180	1,620					1,800
4/13/2021 JAN STOCK TRUST - NEW ISSUANCE										180,000	180	1,620					1,800
NET LOSS																(301,569)	
BALANCE, JUNE 30, 2021		1,665	2	6,925	7	190	0	747,540	748	357,150,583	357,151	79,952,965	1,411	(82,250)	(321,344)	(79,867,074)	522,232

Decision Diagnostic Corp.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	Six Months Ended	
	June 30,	
	2021	2020
Cash flows from operating activities		
Net Loss	\$ (1,511,170)	\$ (17,983,493)
Adjustments to reconcile net loss to		
net cash (used) by operating activities:		
Amortization of prepaid legal fees	-	-
Shares and options issued for services	-	-
Shares issued for financing fees	14,400	16,434,065
Bad debt	218,800	450,000
Loss on write-down of obsolete inventory	-	304,276
Gain on inventory settlement	-	(100,000)
Gain on intellectual property settlement	-	-
Changes in operating assets and liabilities		
Accounts receivable	44,205	(350,039)
Inventory	11,268	(308,771)
Prepaid and other assets	-	1,750
Accounts payable and accrued liabilities	196,177	493,007
Accrued interest	233	180,159
Net cash (used) by operating activities	<u>(1,026,087)</u>	<u>(879,046)</u>
Cash flows from investing activities		
Fixed assets	(35,250)	-
Intellectual property	-	(60,315)
Net cash (used) by investing activities	<u>(35,250)</u>	<u>(60,315)</u>
Cash flows from financing activities		
Proceeds from notes payable	755,000	1,500,030
Payments on notes payable	-	(24,926)
Net cash provided by financing activities	<u>755,000</u>	<u>1,475,104</u>
Net decrease in cash	(306,337)	535,743
Cash - beginning	522,341	114,334
Cash - ending	<u>\$ 216,004</u>	<u>\$ 650,077</u>
Supplemental disclosures:		
Interest paid	\$ -	\$ -
Income taxes paid	<u>\$ -</u>	<u>\$ 1,086</u>
Non-cash transactions:		
Shares and options issued for services	\$ -	\$ -
Shares issued for financing activities	<u>\$ 14,400</u>	<u>\$ 16,434,065</u>
Shares issued for debt and derivative liabilities	<u>\$ -</u>	<u>\$ 1,930,065</u>

The accompanying Notes are an integral part of these financial statements

DECISION DIAGNOSTICS CORP.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED

NOTE 1 – Basis of presentation and accounting policies

Basis of Presentation

The condensed consolidated interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and stated in US dollars, have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures are adequate to make the information presented not misleading.

These statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. It is suggested that these consolidated interim financial statements be read in conjunction with our consolidated financial statements for the period ended December 31, 2020 and notes thereto included in our annual filing. We follow the same accounting policies in the preparation of consolidated interim reports.

Results of operations for the interim periods are not indicative of annual results.

Recent Accounting Pronouncements

Management has analyzed all pronouncements issued during the six months ended June 30, 2021 by the FASB or other authoritative accounting standards groups with future effective dates, and have determined that they are not applicable or are not expected to be significant to our financial statements.

Year-end

We have adopted December 31 as our fiscal year end.

NOTE 2 – Going concern

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. Our ability to continue as a going concern is dependent upon attaining profitable operations based on the development of distribution platforms and channels through which our products that can be sold. We intend to use borrowings and security sales to mitigate the effects of our cash position, however, no assurance can be given that debt or equity financing, if required, will be available. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and classification of liabilities that might be necessary should we be unable to continue in existence.

NOTE 3 – Fair value

Our financial instruments consist principally of notes payable and lines of credit. Notes payable and lines of credit are financial liabilities with carrying values that approximate fair value. Management determines the fair value of notes payable and lines of credit based on the effective yields of similar obligations and believe all of the financial instruments' recorded values approximate fair market value because of their nature and respective durations.

We comply with the provisions of ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value

measurements required under other accounting pronouncements. ASC 820-10-35, “Fair Value Measurements and Disclosures - Subsequent Measurement” (“ASC 820-10-35”), clarifies that fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820-10-35 also requires that a fair value measurement reflect the assumptions market participants would use in pricing an asset or liability based on the best information available. Assumptions include the risks inherent in a particular valuation technique (such as a pricing model) and/or the risks inherent in the inputs to the model. The Company also follows ASC 825 “Interim Disclosures about Fair Value of Financial Instruments”, to expand required disclosures.

ASC 820-10-35 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under ASC 820-10-35 are described below:

Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access.

Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

We utilize the best available information in measuring fair value. The following table summarizes, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of June 30, 2021:

	2021 Fair Value Measurements			
	Level 1	Level 2	Level 3	Total Fair Value
Assets				
Intellectual property	\$ -	\$ -	\$ 3,229,655	\$ 3,229,655
Liabilities	-	-	-	-
Notes payable	-	(3,142,346)	-	(3,142,346)
Total	<u>\$ -</u>	<u>\$ (3,142,346)</u>	<u>\$ 3,229,655</u>	<u>\$ 87,309</u>

NOTE 4 – Equipment – Specialty Manufacturing Instruments

On June 1, 2015, we entered into a wide-ranging manufacturing and product development agreement with a large venture funded Korean concern. On July 8, 2015, we enhanced its role in this agreement through the purchase of, and investment in, computer controlled, specialty manufacturing equipment for our GenUltimate! products that is now located in the Korean facility of the Company’s R&D and contract manufacturing partner. In the summer of 2016 we augmented this equipment by adding additional equipment capable of manufacturing our GenChoice!, GenAccord! and GenCambre! products that make use of different molds and chemical processes.

During the quarter ended March 31, 2017, we acquired \$64,890 in fixed assets pursuant to the manufacturing and product development agreement dated June 1, 2015. We expensed an additional \$380,000 for the development of our GenChoice! product which will make use of the Specialty Manufacturing equipment located in Korea. We continue to incur great expense due to development of our GenChoice! and GenUltimatePrecis!, GenUltimate! TBG and GenViro! products during the three months ending March 31, 2021.

NOTE 5 – Patents

During the three months ended June 30, 2021 and 2020, we capitalized attorney fees related to the continued development and perfection of our patents, the prosecution of new patents, as well as our stable of Trademarks. We did not amortize any intellectual property or patents during the quarters ended June 30, 2021 and 2020. We did, however, prosecute our patents in a lawsuit in the Federal Court district of Nevada, against Johnson and Johnson and two of their divisions. In October 2018 Johnson and Johnson sold their divisions to Platinum Equity. It appears that Platinum did not buy the patent portfolio associated with the diabetes products from Johnson & Johnson when they bought the business operations. Our lawsuit against Johnson & Johnson was ended by the court of Appeals for the Federal Circuit in late 2019.

NOTE 6 – Acquisition of Certain Properties

In March 2014, we agreed to acquire certain properties from Shasta Technologies LLC. The agreement covering this acquisition became the subject of two litigations, one litigation related to the remaining proceeds of an IP defense insurance policy, subsequently settled, the other litigation concerning damages the company is trying to collect from Shasta Technologies LLC owing to Shasta's subsequent undisclosed issues with the U.S. FDA. The damages sought by the company, and other damages, became a part of allegations made in a suit filed in Pennsylvania where we will also litigate damages incurred as a result of a 2015 collusion between Shasta and our former contract manufacturer Conductive Technologies, Inc., who conspired with Johnson and Johnson during the settlement of the first patent litigations. On December 31, 2018 the court in Pennsylvania ordered judgement against Shasta in the amount of \$3,600,000.

The original purchase price for this "Shasta" property was expected to be \$2,000,000 (cash). Earlier in 2019 the company filed a Writ of Execution, owing to the \$3,600,000 judgement that migrated from Pennsylvania. The Writ became final in April 2019, and was used, among other things, as offset against Shasta in the California litigation. Our business with Shasta is now completed.

We did register our FDA cleared product under our FDA Establishment registration (with the US FDA) in 2014, 2015, 2016, 2017, 2018, 2019 and 2020. In September 2016 we became fully compliant with the then newly implemented FDA UDI product identification initiative.

NOTE 7 – Accounts receivable and bad debt

On June 30, 2021, we estimated that we would have approximately \$50,000 in bad debt due to the COVID-19 pandemic which has led to the closing of businesses, particularly those that offer their own product fulfillment services. Accordingly, we have recorded bad debt expense of \$50,000 for the quarter ended June 30, 2021.

NOTE 8 – Notes payable

During six months ended June 30, 2021 the company closed additional financing in the form of Promissory Notes in the amount of \$755,000, with various entities.

NOTE 9 – Stockholder’s equity

Common

During the quarter ended June 30, 2021, we issued 720,000 shares of \$0.001 par value common stock for financing costs totaling \$7,200.

NOTE 10 – Stock options

2017 Stock Option Plan

During the quarter ended March 31, 2017, we adopted the “2017” Executive and Key Man/Woman Stock Option Plan and granted incentive and nonqualified stock options with rights to purchase 20,000,000 shares of \$0.001 par value common stock at the variable strike prices per share based on share fair market value on the date of grant. As of June 30, 2021, all options allowed under the plan have been granted and are exercisable at the election of the holder.

The following is a summary of activity of outstanding stock options under all Stock Option Plans:

	Number of Shares	Weighted Average Exercise Price
Balance, January 1, 2020	26,350,000	\$ 0.05911
Options granted	-	-
Options cancelled	-	-
Options exercised	-	-
Balance, March 31, 2020	<u>26,350,000</u>	<u>\$ 0.05911</u>

NOTE 11 – Commitments and Contingencies

Contingencies and Litigation

We transact commerce in several medical products market channels. We also transact commerce by licensing our proprietary medical software that functions by moving confidential medical data through our proprietary medical information technology devices and networks. Our GenStrip 50 and GenUltimate! products required initial regulatory approval by the US FDA as well as on-going US FDA oversight and inspection during the product life cycle. We also import product from Korea manufactured by our Korean contract manufacturer. This product is also subject to FDA inspection. We are also subject to new FDA regulation and post market overview. In 2016, we had to meet new FDA Guidelines for product identification, tracking and standardization. Our new GenChoice! and GenUltimate! TBG, our GenViro! and the later upcoming GenAccord! and GenCambre! products will follow similar pathways pathway with the U.S. FDA. The FDA calls its new product identification program, the UDI initiative, and the new packaging required, and met by us, approximates a similar standard implemented in the European Union in 2013, and then adopted in other countries, Korea for example. We have, or had our agents file for approvals in the EU and the Russian Federation. In early May 2021 we received approval by the German Agency BfArM (aka) the German equivalent of the U.S. FDA.

Further, our products required medical patient trials and several compete directly with a major platform manufacturer. Healthcare, especially those segments where the company competes, is a very litigious. Competing companies often use litigation as a marketing (market depriving) tool, bringing litigation as a means to protect market share and limit market exposure even though market limitation through litigation is illegal. We have in the past (and currently) defended cases brought by Plaintiffs asserting these types of claims.

The medical industry is also intertwined. From time to time, we have become involved in claims and litigation that arise out of the normal course of business, such as litigation that emerges from disputes over damaged, missing or contaminated product, payment disputes both as a seller and a buyer, and litigation that arises over claims of fair value.

We have also had to defend trade dress claims filed solely because of the cost to defend these claims, real or not. For instance, we have been sued in several jurisdictions over a single business transaction. Often these cases involve substantial over-prosecution where we and our have been held accountable by Plaintiffs for a myriad of things including words written or posted in public forums by anonymous persons.

We may also become involved in disputes that arise over the business or business practices of our suppliers, payers and customers, people or entities that we may not be familiar with. We maintain substantial insurance coverage against suits that may arise over issues of damaged, recalled or counterfeit product and other product liability issues. We have also been a victim of the unapproved acts of prior management. These acts have resulted in claims from individuals and entities since the Board relieved former management of duty in 2006. Nonetheless, these claims have resulted in the use of management time and company resources to investigate, litigate, or settle. In addition, we accrue contingent legal fees and product liability fees. As of June 30, 2021, our contingent legal fees accrual was \$240,000 and our general contingencies accrual was \$245,069. Contingencies total \$485,069 and are reflected herein.

From time to time, we may also be subject to demands from individuals or entities. These demands and disputes may consume management time and company resources. Other than as noted below, if there is such a disclosure, there are no pending matters at the current time that in management's judgment may be considered material or potentially material.

Leases

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is \$3,500 per month (recently raised) on a month-to-month basis. We also maintain space in a public warehouse in Miami, FL, for our import, export and storage and pick and pack needs. Also, we are granted space indirectly in Seoul, South Korea for the completion of necessary clinical trials.

Rent expense totaled \$9,000 and \$9,000 for the quarters ended June 30, 2021 and 2020, respectively.

NOTE 12 – Subsequent events

In accordance with ASC 855, management evaluated all of our activities through the issue date of the financial statements and concluded that except as described below, no other subsequent events have occurred that would require recognition or disclosure in the financial statements. We do however discuss all subsequent events in our Managements' Discussion and Analysis documents and filings.

All Subsequent Events are discussed in detail in our Management's Discussion and Analysis reporting, as has been our practice.

Error Repair

The company will endeavor to repair any and all errors that new sets of eyes find in this document after its posting, whether these errors are in spelling, grammatical, punctuation or numeric. We are not perfect and we remind the readers of this document that they are not perfect either.